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ABSTRACT 
 
 Lin Lin: The role of BP180 in granulopoiesis and NLRP3 inflammasome activation in 
bullous pemphigoid  
(Under the direction of Zhi Liu) 
 
BP180 (also called collagen XVII) is a hemidesmosomal protein. Autoantibodies 
directly against it cause bullous pemphigoid (BP). Gene mutations of BP180 result in 
generalized atrophic benign epidermolysis bullosa (GABEB). BP patients’ autoantibodies 
primarily recognize NC16A domain of BP180; however, there is no cross reactivity 
between human NC16A and mouse homologue termed NC14A. To investigate the 
pathogenesis of BP and identify new functions of BP180, we established humanized 
BP180NC16A (NC16A) mice, and subsequently NC16A domain truncated (ΔNC16A) 
mice.  
In ΔNC16A mice, we discovered a novel function of BP180: this cell-matrix 
adhesion molecule may work on a signaling pathway regulating granulopoiesis.  It was 
recently reported that GABEB or other types of epidermolysis bullosa (EB) patients have 
granulocyte infiltration and eosinophilia. Abnormal granulopoiesis was also observed in 
ΔNC16A mice in addition to skin abnormality.  The affected granulopoiesis originated in 
the stromal cell compartment of the bone marrow because transplantation of bone 
marrow from ΔNC16 mice into wild-type mice corrected the myeloid hyperplasia. In 
addition, ΔNC16 mice at 4 weeks of age also developed myeloid hyperplasia without any 
skin lesions. K14 Cre-driven, skin-specific ΔNC16 mice exhibit similar skin lesions as 
ΔNC16A mice, but had normal granulopoiesis. We demonstrated that NC16A deletion 
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induces NF-kB signaling pathway activation that leads to elevated G-CSF secretion in 
bone marrow and blood. G-CSF regulates granulopoiesis in bone marrow. These findings 
provide a mechanism for clinical relevant pathophysiological observation in BP and 
Junctional Epidermolysis Bullosa (JEB).  
NC16A mice injected with anti-NC16A autoantibodies develop skin disease that 
closely mimics the clinical, immunological and histological features of human BP. 
Previous works have shown that pathological autoantibodies against NC16A, when 
binding to the target on basal keratinocytes, trigger complement activation to generate 
C5a. C5a binding to the C5a receptor on mast cells leads to TNFα release. Mast cell 
recruitment of polymorphonuclear neutrophils is required for disease. However, the 
mechanisms by which mast cells recruit neutrophils to the antibody-binding sites are not 
completely known. We used mice lacking key components of NLRP’s inflammasome to 
test whether mast cell-released TNF-α would act on keratinocyte as first signal and 
pathogenic IgG binding to BP180 as a second signal to activate NLRP3 inflammasome 
in basal keratinocyte. We found that pathogenic antibody-induced BP depends on NLRP3 
activation, leading to IL-1β release and subsequent neutrophil recruitment. Furthermore, 
we showed that IL-1R antagonist, Anakinra, could be an effective drug to treat 
experimental BP.  In this study, we suggest a molecular mechanism for mast cells 
recruitment of neutrophils in experimental BP. More importantly, our findings identify 
potential new therapeutic targets for treatment of BP. 
The findings described in this dissertation explored a novel function of BP180 and 
its mechanism, which would benefit for these symptom-related diseases. BP180 
functional deficiency in bone marrow stromal cells results in highly activated NF-kB 
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signaling pathway that leads to increased G-CSF production and more granulocytes in 
bone marrow and periphery. Our findings also refine our understanding of the 
pathogenesis of BP by demonstrating that NLRP3 inflammasome activation in 
keratinocytes is critical for BP, especially for mast cell recruitment of neutrophils to the 
skin. These findings elucidate a molecular mechanism that would provide a potential 
treatment for BP.  
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
1.1 BP180 
1.1.1 General background 
Bullous pemphigoid is an autoimmune skin blister disease characterized by the 
presence of the separation of epidermis and dermis, deposition of autoantibodies against 
BP180 and inflammatory infiltration in the dermis(1). The gene of BP180 was first isolated 
from human keratinocytes in 1990 and identified as a hemidesmosomal protein by the 
group of Dr. Luis A. Diaz, using sera from patients with bullous pemphigoid(2). The cDNA 
clones encompass 4,699 bases of the BP180 transcript. Structural analysis reveals that 
BP180 is a type II transmembrane glycoprotein: the carboxyl-terminal half of BP180 
consists of 15 collagen domains and 16 non-collagen domains in the extracellular part. 
The main function of BP180 is that it serves as a cell-matrix adhesion molecule through 
its collagenous region, which interacts with basement membrane components(1)(3)(4). 
 BP180 is a highly conserved collagenous protein of the stratified squamous 
epithelium evidenced by the similarity of human, mouse and chicken BP180 
sequences(5). However,  when compared, mouse and human sequences have 86% 
homology(6). Nonetheless, There is  poor cross reactivity between human and mouse 
autoantigens, especially in the NC16A domain(7).  
1.1.2 Gene and cDNA of BP180 
The BP180 gene is localized in the long arm of chromosome 10, locus 10q24.3. 
Human BP180 cDNA was cloned in 1992 by the group of George J. Giudice, using human 
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keratinocytes, while mouse BP180 cDNA was cloned in the same year(5). Sequential 
nucleotide screening of two independently derived human cDNA libraries leads to the 
isolation of a set of overlapping cDNA clones spanning 4,669 bases of the BP180 
transcript and one long open reading frame (ORF), while mouse has a single ~6kb mRNA 
transcript(5). The C-terminal half of human BP180 contains 916 amino acids. Primary 
structure demonstrated tandem repeats of the Glycine-X-Y triple peptides, indicating a 
collagen triple helix component. On the other hand, one clone of mouse BP180 was 598 
amino acids, including ten Glycine-X-Y triplets. In human, within the long collagenous 
region are 15 stretches of non-collagen domains, ranging from 15 to 242 amino acids. 
Seventy-six amino acids upstream of the collagenous region is a putative membrane-
spanning domain (position 502-524), which is flanked by an upstream lysine and two 
downstream glutamate residues. In mouse, another feature of BP180 is the collagenous 
domains separated by non-collagenous segments. However, a computer software 
prediction of BP180 showed it contained one and possibly two transmembrane segments. 
Also, Dr. Li and colleagues identified 7 amino acid segments (amino acids 178-184) as 
potential antigenic sites for development of autoantibodies(8). By prokaryotic expression 
constructs, Dr. Giudice et al. found an autoantibody-reactive site within the protein 
sequence, RSILPYGDSMDRIE (BP180AA#542-555), corresponding to a portion of the 
NC16A noncollagenous domain(9).  
 
1.1.3 Biochemical graph of BP180 
BP180 is a type II transmembrane protein with a C-terminal ectodomain that 
consists of a series of collagen triple helical domains, the function of which is cell-matrix 
3 
 
adhesion. The extracellular domain consists of a C-terminal 1007 amino acid stretch that 
is predicted to extend into the basal lamina region adjacent to the basal keratinocytes, 
which has a series of 15 collagen domains (COL1 through COL15; solid box) and 
stretches of non-collagen sequence (NC1 through NC16a; thin lines). Numbering of the 
collagen and non-collagen domain starts at the C-terminus. The non-collagen domain, 
NC16, encompasses the membrane spanning domain, NC16b, as well as flanking 
regions to the C-terminal and N-terminal sides (NC16a and NC16c, respectively). Domain 
NC16c, the N-terminal segment predicted to be an intracellular domain, includes the four 
tandem repeats(5).  
 
 
 
 
Noncollagenous domain (NC16A) is reported to interact with integrin α6, and the 
N-terminal of BP180 interacts with BP230 N-terminal amino acid residues 1-171 and 555-
Figure 1.1 The molecular structure of BP180. BP180 consists of 15 collagen 
domains (black bars) interspersed by 16 non collagen domains. The non-collagen 
domain called NC16A near the cell membrane is the major autoantigen for bullous 
pemphigoid. (Adapted from Giudice GJ J Invest Dermatol 1992;99(3):243–250.) 
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700(10), while the C-terminal of BP180 is an extracellular domain that interacts with the 
lamina densa. 
BP180, along with BP230, plectin, keratin 5, 14, integrin α6β4, Laminin and type 
VII collagen compose the hemidesmosome. Super resolution microscopy shows the 
hemidesmosome structure in cultured keratinocytes and human skin. Nascent 
hemidesmosomes are associated with individual keratin filaments and β4 integrin. BP180 
surrounds a central core of BP230 molecules(11).  
 
1.1.4 Other functions of BP180 
After cloning BP180, the homology at both the nucleotide and amino acid levels 
was found with chick cornea collagen. Striking conservation in the sizes and positions of 
their collagen domains was observed. In addition to the skin, collagen XVII has been 
reported to be expressed in the buccal mucosa, upper esophagus, ocular cornea, 
conjunctiva, bladder, umbilical cord, placenta, retina and neurons of the central nervous 
system. 
In kidney, BP180 expression by the podocytes is critical for the maturation of the 
structural integrity of the glomerulus and endothelial cells (12). BP180 and BP230 are 
expressed in the CNS and Muller cells of the retina. They  stabilize the synapse by 
anchoring to ECM molecules(13). Using RNA blot, Sipra Aho et al. demonstrated that 
BP180 is expressed in a variety of tissues with a predominant epithelial component such 
as mammary, salivary and thyroid glands, colon, prostate, testis, placenta and adult and 
fetal thymus, as well as in colon, pancreatic and prostatic adenocarcinoma cell lines and 
ovarian carcinoma(14). More importantly, they also found expression of BP180 in skeletal 
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muscle and spleen. Therefore, BP180 expresses in a variety of normal tissues with an 
epithelial component.  
 
1.1.5 Bullous pemphigoid 
Bullous pemphigoid (BP) was first described by Lever in 1953, the hallmark of 
which includes tense, sub-epidermal bullae associated with inflammatory infiltration 
(15)(16).  
Bullous pemphigoid is a skin subepidermal blistering autoimmune disease, 
occurring most commonly in elderly patients. The first signs of skin lesions are urticarial 
plaques of the trunk and extremities, then present tense blisters, sometimes producing 
an extensive and striking bullous eruption(16). Histological examination in bullous 
pemphigoid shows subepidermal blistering, with many infiltrating polymorphonuclear 
(PMN) cells along the basement membrane and within the blister cavity. Eosinophils are 
prominent cells in the infiltrate. Direct immunofluorescence of perilesional skin shows IgG 
and C3 deposition along the basement membrane. Indirect immunofluorescence of serum 
shows circulating IgG autoantibodies that bind to the basement membrane of human 
skin(17). Researchers were trying to develop an animal model of BP since the 1970s 
based on autoantibody triggered blister formation. However, due to the amino acid 
sequence of NC16A, human BP180 protein autoantigen recognized by patient’s 
autoantibodies is very poorly conserved in murine BP180 NC14A, and failed to 
demonstrate the clinical activities of BP in the animal. To overcome this obstacle, in 1993 
Dr. Liu cloned and expressed the NC14A portion of mBP180 and immunized New 
Zealand White rabbits.  When intradermally injected with polyclonal IgG serum from 
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rabbits, neonatal Balb/c mice developed similar clinical signs as BP patients: blister 
formation, deposition of IgG and complement at the basement membrane, dermal-
epidermal separation,  and PMN infiltration(18).   After Dr. Liu, Zhi and colleagues 
established the animal model successfully, the breakthrough discoveries of pathogenesis 
in BP were revealed. Using this in vivo system, Dr. Liu and colleagues elucidated the 
roles of complement, neutrophils, mast cells and proteolytic enzymes that are involved in 
disease progress(17)(19)(20)(21)(22)(23). Autoantibodies bind to the basement 
membrane BP180 NC16A and activate complement, a major involved component of 
which is C5a.  Because using cobra venom factor to deplete complements or C5a 
deficient mice are resistant to pathogenic effects of anti-BP180 IgG(19) . Complement 
activated classical pathways because C4-/- mice are resistant to experimental BP and 
anti C1q antibody treatment completely abolished subepidermal blistering. Alternative 
pathway is necessary for the full development of experimental BP since Fb gene deficient 
mice have a delayed and less intense disease phenotype(24). Complement C5a and 
mast cells (MC) are critical for pathogenesis of experimental BP, evidenced when mice 
deficient in MCs or the C5a receptor failed to develop subepidermal blisters when injected 
with pathogenic anti-BP180 IgG(25). Furthermore, Lisa and colleagues demonstrated 
p38 MAPK phosphorylation is important for mast cell degranulation by C5a activated 
C5aR on mast cells(26). After degranulation, mast cells release TNF-α. Mast cells release 
other cytokines or through macrophage recruitment PMN. In experimental BP, 
subepidermal blistering is triggered by rabbit anti-murine BP180 IgG and depends upon 
complement activation, mast cell degranulation, and neutrophil infiltration. There are four 
classes of FcRs for IgG: FcγRI, FcγRII, FcγRIII and FcγRIV. FcγRI, FcγRIII and FcγRIV 
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are activating FcR, while FcγRII is inhibiting FcR. To elucidate the role of different FcγR 
on neutrophils in bullous pemphigoid, FcγRI-/-, FcγRII-/-, FcγRIII -/- genes deficient mice 
were used. FcγRIII-/- mice were resistant to BP, which indicates that FcRn is a potential 
therapeutic target for IgG mediated autoimmune diseases(27)(28). 
Neutrophil recruitment is an important event in experimental bullous pemphigoid, 
since using different methods to deplete neutrophils or neutropenia mice are resistant to 
bullous pemphigoid(20). Neutrophils,  along with other inflammatory cells infiltrate the skin 
blister, and release granules(23). Neutrophil granules contain a variety of proteolytic 
enzymes, including elastase(NE), cathepsin, collagenase, and gelatinase B(GB) 
(29)(30)(31). Taking advantage of gene deficient mice, Dr. Liu and colleagues have 
demonstrated that both NE-/- and GB-/- mice are resistant to disease by passive 
transferred pathogenic BP IgG autoantibodies(23)(32).  Both NE-/- and GB-/- mice did not 
show affected of neutrophil migration to skin at 4 hour time course(32). Furthermore, the 
function of GB and NE in experimental BP has been elucidated. GB acts upstream to 
regulate NE activity by inactivating of α1-proteinase inhibitor (α1-PI)(33).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Two types of bullous pemphigoid mouse model have been established: one is passive 
transfer of autoantibodies(18); the other is injection of recombinant peptides(34). A 
recently reported mouse NC14A gene deficient animal model develops blistering, 
autoimmunity and itching, which has both inherited (spontaneous blisters) and acquired 
(pruritus, blistering, and development of autoantibodies) bullous skin disease(35). 
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1.1.6 Junctional epidermolysis bullosa (EB) 
Another BP180 related disease is called epidermolysis bullosa (EB). EB refers to 
a group of heterogenous heritable disorders characterized by formation of blisters at sites 
of minor friction or trauma(36). 14 gene mutations have been identified within the 
cutaneous basement membrane zone(37).   
There are four types of epidermolysis bullosa based on the level of tissue 
separation within the cutaneous basement membrane zone: epidermolysis bullosa 
simplex, junctional epidermolysis bullosa, dystrophic epidermolysis bullosa and Kindler 
syndrome (38)(39). 
 
Figure 1.2 The pathogenesis of experimental bullous pemphigoid. Pathogenic 
autoantibody binds to BP180 on basal keratinocytes and triggers complement 
activation and the generation of C5a. C5a induces mast cell degranulation dependent 
p-p38 MAPK activation and releases proinflammatory mediators. Recruitment of 
neutrophils, and pathogenic IgG Fc activates PMN, then PMN release proteinases, 
which degrade the extracellular matrix and cause blistering. 
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.  
Figure 1.3 The categories of epidermolysis bullosa (EB). Based on the level of 
tissue separation, there are four types of EB: epidermolysis bullosa simplex; junctional 
epidermolysis bullosa; dystrophic epidermolysis bullosa and Kindler syndrome. 
(Adapted from Daisuke Sawamura, J. Dermatol. 2010;37(3):214–219.) 
 
From the diagram we can see that BP180 is associated with the epidermis, the 
basement membrane zone and the dermis. Therefore, BP180 mutations could cause EB 
simplex, dystrophic EB and most reported junctional EB(40)(41)(42). Junctional EB is 
involved with abnormal hemidesmosomal protein. Unlike BP230, BP180 is a 
transmembrane protein that interacts with the integrin protein formed hemidesmosome 
complex. BP180 mutations cause one form of junctional epidermolysis bullosa called 
generalized atrophic benign epidermolysis bullosa(GABEB)(42). BP180 was first 
identified as an inherited disease right after BP180 was isolated and identified as the 
major antigen for bullous pemphigoid. In 1995, case related deficient expression of BP180 
has been reported (43).Immunoblotting analysis demonstrated that sera from patients 
with generalized atrophic benign epidermolysis bullosa (GABEB) lack cross-reaction with 
cultured keratinocytes, while Northern blot showed that the amount of BP180 transcripts 
were reduced. Interestingly, sera from one patient with GABEB showed interrupted 
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staining for BP180, which might imply GABEB patient could have anti-BP180 
autoantibodies.  Furthermore, GABEB caused by deficiency of BP180 is characterized as 
the autosome recessive form(42). 
The clinical features of GABEB are continuous blistering since birth, cigarette 
paper-like atrophic depigmented skin at sites of recurrent blistering (no scarring or milia), 
normal growth and lack of anemia, moderate improvement during aging, dystrophic nails 
and dentition, mild mucous membrane involvement, and a typical pattern baldness with 
significant scalp atrophy, partial absence of eyelashes and eyebrows, and absence of 
pubic and axillary hair. GABEB could also be caused by lamini-5 deficiency. Although 
there is no specific or effective treatment for epidermolysis bullosa yet, gene therapy, 
protein replacement therapy, and cell-based therapies have been 
developed(44)(45)(46)(47)(48).  
Generalized JEB is distinct from Herlitz disease by its absence of anemia and 
growth retardation, however in the BP180 gene deficient mouse model, the phenotype of 
runt was observed.  
Interestingly, in JEB patients, eosinophilia and infiltration with eosinophils in the 
skin have been reported(49)(50)(51)(52). The main feature of epidermolysis bullosa is 
recruitment and activation of granulocytes, of which the granulocyte dependent 
inflammatory pathway is involved in the autoimmune tissue damage. However the 
mechanisms underlying the increase of granulocytes in JEB are unknown.  
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1.2 Inflammasome 
1.2.1 General background 
The inflammasome is a molecular platform triggering activation of inflammatory 
caspases and processing of pro-IL-1β(53). The Inflammasome comprises caspase-1, 
ASC, and NOD-like Receptor ( a Pyrin domain-containing protein sharing structural 
homology with NODs)(53). IL-1β and IL-18 activation depends on caspase-1, evidenced 
by caspase-1 gene deficient mice, which have a defect in the maturation of pro-IL-1β and 
pro-IL-18 and are resistant to the lethal effect of endotoxins(54)(55). Pyroptosis is 
caspase-1 dependent cell death, resulting in cellular lysis and release of the cytosolic 
contents(56). NOD-like receptor is a conserved protein that contains an N-terminal Pyrin 
domain, a central NACHT domain and a C-terminal leucine-rich repeat (LRR) region. The 
NLRs that have the Pyrin domain (PYD) interact and recruit the adaptor ASC via PYD-
PYD hemophilic interaction. ASC contains an N-terminal PYD and a C-terminal CARD 
and is an essential component for some inflammasome formation(57). The CARD domain 
associates directly and specifically with the CARD domain of procaspase-1 through 
CARD-CARD interactions(58).  Whereas NLRP1 and NLRC4 can be activated by 
microbial stimuli such as anthrax lethal toxin and Salmonella sp., respectively, AIM2 is 
activated by the presence of DNA in the cytoplasm(59)(60)(61)(62). The NLRP3 
inflammasome is extensively investigated and is activated by multiple stimuli, such as 
extracellular adenosine triphosphate (ATP), gout-associated monosodium urate (MSU) 
crystals, asbestos, silica, alum, titanium dioxide, nigericin, and Candida albicans. One 
well-accepted explanation is that the NLRP3 inflammasome is not likely the direct 
receptor for pathogen- associated molecular pattern (PAMP) or damage-associated 
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molecular pattern (DAMP), rather that it senses cellular homeostasis changes(63). In this 
introduction, we focused on the NLRP3 inflammasome.  
 
1.2.2 Mechanisms of NLRP3 Inflammasome activation 
After the NLRP3 inflammasome senses the disturbances in cellular homeostasis, 
there are some common cellular events that serve as the activation signals for the NLRP3 
inflammasome, including potassium efflux, generation of reactive oxygen species, and 
cathepsin B release(64). The NLRP3 inflammasome is not activated when K+ efflux is 
prevented by a drug or a high concentration in the media(65). The mechanism is that 
extracellular ATP engages the ATP-gated cation channel P2X7R whereas bacterial toxins 
cause membrane pore formation to trigger K+ efflux(66).  The generation of reactive 
oxygen species (ROS) is considered a cellular event that causes NLRP3 inflammasome 
activation, evidenced by ROS blockade via chemical inhibitors or gene knockdown 
suppressed inflammasome activation(67)(68). The third molecular mechanism which 
activates the NLRP3 inflammasome is cathepsin B release. Uptake the crystalline and 
particulate activators causes destabilization of the acidic lysosomal compartment and 
releases cathepsin B trigger inflammasome activation(69).  
The formation of the inflammasome complex is essential for the activation of the 
NLRP3 inflammasome. So, the locations of different components are critical for activation 
of the inflammasome. Previous reports based on biochemical and imaging methods 
demonstrate that NLRP3 inflammasome activation dependents on relocalization from a 
cytosolic compartment to the mitochondria(70)(71)(63). Possible reasons for this 
phenomenon are that the NLRP3 inflammasome assembles on mitochondria, providing 
13 
 
some cues for NLRP3 activation, such as mitochondrial reactive oxygen species (mROS), 
mitochondrial DNA (mtDNA), and phospholipid cardiolipin(63). ASC relocalization from 
the nucleus to the cytosol, and forming a large perinuclear aggregate is also an indicator 
for inflammasome activation(72). 
 
1.2.3 Inflammasome related diseases and therapeutics 
Human NLRP1 is genetically linked to a group of autoimmune and 
autoinflammatory diseases, such as vitiligo, autoimmune thyroid diseases, type I diabetes, 
multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, atherosclerosis, and 
obesity(73)(74). The NLRP3 gene is associated with various autoinflammatory disorders 
such as Muckle-Wells syndrome (MWS)(75), familial cold autoinflammatory syndrome 
(FCAS)(76), and chronic infantile neurologic cutaneous and articular syndrome 
(CINCA)(77).  Inflammasome signaling pathway inhibitors, antagonists of IL-1R and 
antibodies against products of Inflammasome activation have been explored for treatment 
of inflammasome related diseases. Even though IL-1β and IL-1α, independent of 
Inflammasome pathway, share IL-1R, an IL-1R antagonist  Anakinra,  an FDA approved 
treatment for rheumatoid arthritis,  is well-recognized for treatment of inflammasome 
related diseases(78). The neutralizing IL-1β antibody Canakinumab and the soluble 
decoy IL-1 receptor Rilonacept are also approved for treatment of inflammasome related 
gene mutation diseases and Cryopyin-Associated Periodic Syndromes (CAPS)(78). 
NLRP3 specific inhibitors have also been explored, including Glyburide and MCCP950.  
Glyburide, a small molecule inhibitor for NLRP3, is the most widely used sulfonylurea 
drug for the treatment of type 2 diabetes, which works by inhibiting ATP-sensitive K+ 
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channels(79). MCCP950 is a highly selective inhibitor of the NLRP3 inflammasome and 
a diarylsulfonylurea-containing compound, by  molecular targeting of NLRP3 itself or is 
closely linked to the activation of NLRP3, instead of blocking K+ efflux or Ca2+ influx by 
mechanisms of which structurally related drug Glyburide, so MCCP950 blocked both 
canonical and noncanonical NLRP3-dependent inflammasome activation(80)(81). 
 
1.3 Granulopoiesis 
1.3.1 Granulocyte development  
Neutrophils are the most abundant leukocytes in blood, comprising 60-70% of all 
circulating white blood cells.  Neutrophil differentiation from bone marrow hematopoietic 
stem cells is regulated by the coordinated expression of three myeloid transcription 
factors, GFI-1, PU.1 and members of the CCAAT enhancer binding protein family 
(C/EBPs). The balance between PU.1 and C/EBPα determines whether myeloblasts 
differentiate into granulocytes (high C/EBPα) or monocytes (high PU.1)(82).  
Pluripotent hematopoietic stem cells (HSC) could give rise to a lin-IL7R-KIT+Sca-
1-CD34+FcrRlo common myeloid progenitor (CMP), CMPs can give rise to all classes of 
myeloid cells(83)(84). Common myeloid progenitors give rise to either 
megakaryocytes/erythrocytes or granulocyte/macrophage progenitors(GMP)(83). 
Neutrophils, eosinophils and basophils constitute the three main types of granulocytes. 
Large quantities of neutrophils are produced and stored in the bone marrow(85). 
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1.3.2 Extrinsic factor for granulopoiesis 
NF-kB, a transcription factor, is involved in cellular processes of proliferation and 
differentiation of hematopoietic lineages. IkBα is an inhibitor of NF-kB in its canon 
signaling pathway.  IkBα was phosphorylation by kinase, followed by degradation of IkBα 
and subsequent translocation of NF-kB to the nucleus.  Mice deficient in IkBα develop a 
hypergranulopoiesis. However, specific deletion of IkBα in neutrophils and macrophages 
or hematopoietic stem cells did not result in granulopoiesis, despite constitutive NF-kB 
activation in these cells. This establishes the relevance that NF-kB signaling pathway of 
nonhematopoietic cells control and regulate granulopoiesis. The signaling pathway in 
stromal cells could induce granulopoiesis. Extensive investigation reports ubiquitous 
deletion of IkBα in non-hematopoietic cells(86)(87).  
The granulocytes of IkBα gene deficient mice express high levels of the 
transmembrane receptor Notch1, a key regulator of cell-fate decisions during 
differentiation.  
 
1.3.3 Granulocyte circulation 
Granulocytes are an important player in innate immunity for defense in the immune 
responses to foreign pathogens, however abnormal granulocyte accumulation and 
activation leads to a number of inflammatory diseases. Thus, homeostasis and the 
dynamic process of granulocyte production, mobilization and subsequent clearance is a 
delicately orchestrated series of events. Neutrophils are produced in bone marrow and 
regulated by G-CSF and CXCR4 for either exiting or staying in bone marrow. Upon 
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infection or the stimulation of inflammation, granulocytes would emigrate from bone 
marrow by gradient change of cytokines and chemokines(88).  
Mature granulocyte egress from bone marrow to the circulation is the process for 
the body to respond to infection or inflammation. Mobilization of granulocytes from the 
bone marrow to sites of inflammation is regulated by cytokines or chemokines, such as 
chemokine macrophage inflammatory protein-2(cxcl2)(89); KC(cxcl1); leukotriene B4, 
C5a and IL-8 et al(90)(91)(92). CXCR4 is important for granulocyte retention in bone 
marrow by interacting with bone marrow stromal cell-derived factor (SDF-1a)(93). Using 
CXCR4 antagonist demonstrated that rapid release of granulocytes indicates that SDF-
1a is a critical factor for detaining granulocytes in bone marrow, whereas mutation of 
CXCR4 in patients with hypogammaglobulinaemia, infection and myelokathexis (WHIM) 
syndrome showed normal bone marrow granulocytes but neutropenia in the 
circulation(94).  
In gene deficient G-CSF or G-CSFR mice, there are very few neutrophils, both in 
the bone marrow and the blood, which demonstrates that G-CSF regulates both 
granulopoiesis and mobilization of granulocytes from bone marrow. G-CSF’s control of 
granulocyte mobilization may result from reduced production of SDF-1a or down-
regulated CXCR4 expression on granulocytes(95).  
Since the half- life of neutrophils in circulation is about 6.5hr, and 1011 cells are 
released from bone marrow to circulation per day, clearance in the homeostatic conditions 
is the important question to be investigated(88). Both inflammation sites and bone marrow 
are the location for neutrophil clearance. It is possible that SDF-1a and CXCR4 axis is 
important for neutrophils homing back to bone marrow(96). About 30% of neutrophils 
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home back to the bone marrow under homeostatic conditions, which is cleaned by 
resident macrophages(97).  
1.3.4 Granulocytes’ function and disease 
There are four fundamental types of granules in neutrophils. The first type is 
primary granules. Azurophilic granules are the largest and are first formed during 
neutrophil maturation, including myeloperoxidase (MPO), defensins, lysozyme, 
bactericidal/permeability-increasing protein(BPI), neutrophil elastase (NE), proteinase 
3(PR3), and cathepsin G(CG). The second class of granules, the specific granules, is 
characterized by the presence of the glycoprotein lactoferrin. The third class, the 
gelatinase(tertiary) granules, serve as a storage location for a number of 
metalloproteases, such as gelatinase and leukolysin.  The fourth set are the secretory 
vesicles, in the end stages of neutrophil maturation(98)(99)(100).  Granulocytes execute 
their function through release of granule proteins, and granular components serve as 
signaling molecules for subsequent inflammatory cell recruitment(101). Neutrophils are 
professional killer, they are an important player in innate immunity because they release 
peptides and proteins to kill microbes. There are three main types of antimicrobials: 
cationic peptides and proteins that bind to microbial membranes(102)(103); 
enzymes(104)(105); and proteins that deprive microorganism of essential 
nutrients(106)(107). Neutrophils can produce ROS in a respiratory burst process, which 
can direct antimicrobial action and modify host molecules(108)(109). Neutrophils also 
have phagocytosis ability, by which they direct removal of pathogens and cell debris. 
Neutrophils directly recognize PAMPs by pattern-recognition receptors, or opsonin 
mediated, FcγR-mediated phagocytosis. More recently investigated mechanisms by 
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which neutrophils clear high local concentration of microbes are neutrophil extracellular 
traps. Upon cues from outside, neutrophils undergo NETosis, an active form of cell death 
that leads to release of decondensed chromatin into the extracellular space(110). The 
failure to remove apoptotic neutrophils leads to the accumulation of cytotoxic substances 
and is associated with cystic fibrosis, chronic obstructive pulmonary disease (COPD) and 
rheumatoid arthritis (RA)(111)(112)(113). Inflammation is also involved in cancer. 
Neutrophil derived ROS can initiate tumor formation by genotoxic stress and induction of 
genomic instability(114)(115). Neutrophils produce angiogenic factors, enhance 
metastasis, and suppress the antitumor immune response functions to promote tumor 
growth(116)(117). Neutrophils also are associated with autoimmune diseases due to 
deregulated cell death and clearance. NETosis may related to autoimmune disease 
systemic lupus erythematosus (SLE)(118). Recruitment of inflammatory cells to joints is 
the hallmark of rheumatoid arthritis (RA). Neutrophils are the critical immune cells 
necessary for the development of joint inflammation and damage. NETs are observed in 
the synovial tissue of RA and serum levels of MPO increase in patients with RA(119).  
 
1.3.5. Granulocytes and B cell development 
Development of B cells is an orchestrated and dynamic sequential process from B 
lymphopoiesis in bone marrow and liver. This process occurs through discrete stages 
driven by the sequential rearrangement and expression of genes, including lineage 
transcription factor expression and extrinsic cue stimulation. Bone marrow stromal cells 
induce hematopoietic stem cell differentiation to common lymphoid progenitor cells (CLPs) 
either through direct interaction or indirect secreted cytokines, chemokines or growth 
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factors. CLPs are capable of generation of B and T cells in bone marrow and then B cells 
proliferate, differentiate and mature in bone marrow and secondary lymph organs. T cells 
will undergo those processes mostly in thymus. The hallmark of B cell development is the 
rearrangement of the B cell receptors. The stages in primary B-cell development are 
defined by the sequential rearrangement and expression of heavy (Igµ) and light chain 
(Igk or Igλ) immunoglobulin genes. The early stages of B cell development are dependent 
on bone marrow stromal cells. Stromal cell expressed adhesion molecule VCAM-1 
interacts with integrin VLA-4 or other cell-adhesion molecules (CAMs). These interactions 
promote pro-B cell’s receptor tyrosine kinase Kit with stromal cell’s stem cell factor (SCF), 
which would induce proliferation of the B-cell progenitors. IL-7 is the important cytokine 
for the late stage of B cell proliferation and development. After IL-7 feeds B cell progenitor 
proliferation, D-J rearranging of H-chain genes occurs. In the late pro-B stage, V-DJ 
rearranges. When the  µ chain is transiently expressed on the B cell surface, B cells 
undergo the pre-B cell stage, and IgM is expressed on immature B cell surfaces.   Mature 
B cells express both IgM and IgD immunoglobulins. B cell function could be classified as 
T-dependent or T-independent function, depending on whether T cell help is needed 
(120)(121). T dependent function of B cells would be via direct contact or secret 
lymphokines(121). The hypothesis on how granulopoiesis affects B cell development will 
be discussed in Chapter 4, 4.4. 
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CHAPTER 2: DEFICIENCY OF THE HEMIDESMOSOMAL PROTEIN BP180 
FUNCTION LEADS TO ALTERED GRANULOPOIESIS IN MICE 
 
2.1 Introduction 
 BP180 (also termed type XVII collagen) is a transmembrane hemidesmosomal 
protein and plays a critical role in cell-cell matrix adhesion in the skin. This structural 
property of BP180 was identified based on two human subepidermal blistering diseases: 
the anti-BP180 autoantibody-mediated autoimmune blistering disease bullous 
pemphigoid (BP)(1)(2)(3), and BP180 gene mutation-caused generalized atrophic benign 
epidermolysis bullosa (GABEB)(4)(5)(6). However, other functions of BP180 are largely 
unknown. 
BP is the most common skin autoimmune blistering disease. It is characterized by 
autoantibodies directed against the hemidesmosomal proteins BP230 and BP180, 
dermal-epidermal junction separation and inflammatory cell infiltration (7). Patients with 
BP have eosinophils and neutrophils in the bullous cavity and dermis of the lesional skin. 
BP180 is a transmembrane homo-trimeric glycoprotein with a subunit MW of 180 kDa 
(8)(9)(10).  Its C-terminal ectodomain consists of a long collagenous stretch interrupted 
and flanked by 16 non-collagen sequences(11). The membrane-proximal non-collagen 
16A (NC16A) linker domain harbors multiple epitopes recognized by BP 
autoantibodies(12)(13). Although the human BP180 shares high overall homology with 
the murine BP180, the NC16A domain is very poorly conserved with the equivalent 
domain in the murine protein (NC14A), resulting in a lack of immune cross-reactivity 
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between these two species (3). Animal models of BP demonstrated that anti-NC14A and 
anti-NC16A antibodies induce subepidermal blistering in mice associated with neutrophil 
infiltration (2) (3).   
 
Junctional epidermolysis bullosa (JEB) is a group of rare genetic diseases 
characterized by marked skin fragility and blister formation following minor trauma,  
sometimes along with eosinophilia, eosinophils and/or neutrophils infiltrated in the dermis 
and autoantibodies deposited at the basement membrane zone(14). GABEB is a subset 
of EB and caused by BP180 gene mutations(15). Patients with GABEB develop 
subepidermal blistering(15)(16). Previous reports demonstrated that deletion of NC14A 
domain of mouse BP180 led to loss of cell-cell matrix adhesion and granulocyte  
infiltration in the skin(17). However, the mechanisms underlying the increased 
granulocytes in JEB patients and mice lacking BP180 function are unknown.   
Pluripotent hematopoietic stem cells (HSC) could give rise to a lin-IL7R-KIT+Sca-
1-CD34+FcrRlo common myeloid progenitor (CMP), and CMPs could differentiate into 
megakaryocyte/erythrocyte and granulocyte/macrophage progenitors (GMP) (20). 
Neutrophils, eosinophils and basophils constitute the three main types of granulocytes. 
Large quantities of neutrophils are produced and stored in the bone marrow(18). 
Granulopoiesis is regulated by cell-autonomous and non-cell-autonomous mechanisms 
(19)(20). G-CSF is a major determinant of non-cell-autonomous mechanism in the course 
of granulocytes differentiation, proliferation and maturation(21).  G-CSF is secreted by 
bone marrow stromal cells, endothelial cells, macrophages and fibroblast cells(22). 
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Deficiency of G-CSF or G-CSF receptor exhibits neutropenia in mice, demonstrating that 
G-CSF is an important extrinsic regulator for neutrophils(22).  
Homeostasis of hematopoietic stem cells (HSCs) in bone marrow and peripheral 
are dependent on multiple signaling pathways.  Notch and NF-kB are two of the most 
investigated signaling pathways(23)(24). Previous study showed that bone marrow niche 
regulates hematopoiesis in a NF-kB dependent manner(25)(26). NF-kB transcription 
factor activation leads to proinflammatory cytokines and G-CSF production(27)(28).  Loss 
of transcriptional repression of NF-kB activation in IκBα-deficient mice leads to an 
uncontrolled expansion of myeloid cells via G-CSF(29)(30). BP180 was reported to be 
involved in NF-kB signaling pathway in cultured keratinocyte (31).  
In this study, we generated a novel mouse strain lacking BP180 function by 
deleting the NC16A domain of the molecule and investigated new functions of BP180. 
We show that deletion of the BP180NC16A domain leads to significant alterations of 
granulopoiesis by affecting the activation of NF-kB signaling pathway and G-CSF 
expression in bone marrow stromal cells.  
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2.2 Materials and methods 
Generation of ΔNC16A mice 
Humanized NC16A mice were described previously (2)  Briefly, mouse BP180 
Exons 17 and 18 encoding NC14A domain were replaced by human BP180 exons 18 
and 19 encoding NC16A domain flanked by loxp sites (also see Figure 1A). NC16A mice 
(on C57BL/6J background) were then bred with germline Cre mice (on C57BL/6J 
background, The Jackson Laboratory, Maine, USA); leading to removal of human exons 
17 and 18 cassettes and expression of NC16A truncated BP180 in ΔNC16A mice. Mice 
with skin-specific deletion of NC16A were generated by crossing NC16A mice with 
K14Cre mice (on C57BL/6J background)(32)(33). All the mice were bred and hosted 
under specific pathogen-free conditions in the animal facilities of the University of North 
Carolina, Chapel Hill. Animal care and animal experiments were conducted in accordance 
with the Animal Care Committee at the University of North Carolina, Chapel Hill. 
 
Transplantation 
C57BL/6 (CD45.1and CD45.2) mice were purchased from National Cancer 
Institute and housed under specific pathogen-free conditions in the animal facilities of the 
University of North Carolina, Chapel Hill. To make mixed bone marrow chimera, bone 
marrow from ΔNC16A CD45.2 and wild type CD45.1 mice were mixed at 1:1 ratio, and 
then 5X106 cells were transplanted to sub-lethal irradiated (700 cGy) WT CD45.1.2 
recipient mice by I.V. administration(34). 
 
Bone Marrow Derived-Mesenchymal Stem Cells Culture 
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Bone marrow cell isolation and culture were as described(35). Briefly, bone 
marrow cell suspensions were isolated from 8-12 weeks ΔNC16A and WT control mice 
by flushing the marrow from femurs a few times with 10 ml PBS/2%FBS in syringe with a 
22-G needle. The cells were centrifuged for 5 min at 1000 rpm, 4°c after red blood cells 
were lysed and removed. Cells were counted and seeded with MSC culture medium 
(MesenCultTM MSC culture medium, stem cell technologies, Vancouver, Canada) 
according to the protocol provided by the manufacture.  
 
CFU assay 
The colony forming capacity of bone marrow cells was estimated in mouse 
methylcelluose complete media, according to the manufacturer’s instructions (R&D 
System Inc. MN). Briefly, 3×104 bone marrow mononuclear cells were mixed well in 1 ml 
media, plated in 3 cm diameter culture dishes, and then incubated at 37°C in a 5% CO2 
incubator. After 9 day culture, the total number of colonies in each dish was counted under 
a microscopy(36) . 
 
Flow cytometry 
Bone marrow, spleen, lymph node and peripheral blood were taken from mice. 
Bone marrow single cell suspension were made by flushing femurs a few times by 22 G 
needle and 10 ml syringe with 10 ml PBS/2%FBS. Spleen and lymph node were mashed 
by slides carefully and then passing through 70 um cell strainer (FALCON, Corning, NY) 
to isolate single cell suspension. All cell suspensions were treated with ACK buffer for red 
blood cell lysis. 5x106 cells were used for staining.  Cells were stained by anti-Gr.1 Apc-
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cy7, anti-CD11b, anti-CD3, anti-CD19, anti-Gr.1 PerCp, anti-CD11b PerCp, Anti-CD3 
PerCp, anti-CD19PerCp, anti-CD127 PE, anti-CD34 Pacific Blue, anti-CD16, anti-CD19 
PO, anti-Sca-1 FITC, anti-c-kit Pe-cy7. Anti-Gr.1, anti-CD11b antibodies were used to 
detect granulocytes. Anti- CD3 antibody was used to detect T cells. Anti-CD19 antibody 
was used to detect B cells. Anti-CD127, CD34, CD16, Sca-1 and c-Kit antibodies were 
used to identify different population of granulocyte progenitors (Figure 3A). These 
antibodies were purchased from Biolegend (San Diego, CA).  
 
Immunoblotting and immunofluorescence 
Immunoblotting and immunofluorescence for BP180 were performed by using 
standard techniques as previously described (2). The anti-NC16A antibody was from BP 
patient serum, while rabbit anti-NC1-3 polyclonal antibody was made in house.  Femurs 
were fixed in 4% paraformaldehyde overnight and then decalcification by 14% EDTA 
overnight and then tissue was rinsed by PBS 3 times. The femurs were fixed in OCT 
(Tissue-TEK®, CA, USA). Cryosections of the OCT-embedded femurs were stained and 
were imaged by a Zeiss LSM 700 Confocal Laser Scanning Microscope and ZEN imaging 
software. The pictures were analyzed by Image-J software. Bone marrow cells and bone 
marrow derived mesenchymal stem cell (1x106) were used for NF-kB signaling pathway 
determination.  After Pierce®BCA protein assay (Thermo Scientific), proteins were 
probed by the following antibodies, anti-phospho-p38, anti-p38, anti-phospho-JNK, anti-
JNK, anti-Phospho ErK, anti-ErK, anti-IκBα, anti-phospho-IκBα, anti-rabbit secondary 
antibody (Cell Signaling Technology®,MA, USA).  
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Quantification of G-CSF, GM-CSF by ELISA 
Levels of G-CSF and GM-CSF in bone marrow supernatant and serum samples 
from ΔNC16A, K14Cre ΔNC16A and WT control mice were quantified by ELISA kits 
according to the procedures provided by the manufacture (Abcam, MA, USA). ELISA 
Max™ Mouse GM-CSF ELISA kits were purchased from Biolegend. To collect bone 
marrow supernatants, marrows from femurs were flushed out with PBS and centrifuged. 
Collected supernatants were stored in -80°C before use. 
 
Statistical analysis 
The data are expressed as mean±SEM and were analyzed using the Student’s t-
test. A p value less than 0.05 was considered significant.  
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2.3 Results 
Generation and characterization of conditional ΔNC16A mice 
Previously we generated humanized NC16A mice to investigated pathogenesis of 
BP, since anti-BP180NC16A autoantibodies from BP patients lack cross-activity with 
mouse BP180NC14A domain(2). In NC16A mice, the exons encoding mouse NC14A 
domain were replaced by exons 18 and 19 encoding human NC16A domain (Figure 2.1A). 
We purposely flanked the exons 18 and 19 with lox P sites for future deletion of NC16A 
to identify new functions of BP180. When NC16A mice were crossed with germline Cre 
mice, Cre recombination enzyme removes the loxP-flanked exons 18 and 19 and 
maintains the remaining reading frame, resulting in mice expressing NC16A domain 
truncated BP180 (this whole body deleted NC16A mice were termed ΔNC16A or -/- mice). 
Similar to previously described mice lacking NC14A domain (17), the novel conditional 
ΔNC16A mice showed no clinical skin phenotypes after birth but began to develop minor 
skin lesions at the age of 8-12 weeks and erosions mostly on snout and ears after 16 
weeks old (Figure 2.8A).  ΔNC16A mice also showed retarded growth (Figure 2.8B). 
Genotyping of mouse tail DNA confirmed the lack of exons 18 and 19 in ΔNC16A mice 
(data not shown). As expected, immunoblotting of skin protein extracts demonstrated that 
anti-NC16A antibody reacted with full-length BP180 in WT and not NC16A truncated 
BP180 in ΔNC16A mice, while anti-NC1-3 antibody recognized both full-length and 
NC16A truncated BP180 (Figure 2.1B). Necropsy on 8-12 weeks old ΔNC16A mice 
revealed splenomegaly and bone marrow color change from pink to gray in ΔNC16A mice 
(Figure 2.1C). Spleen/body weight ratio was significantly increased in ΔNC16A compared 
to WT control mice (Figure 2.8C). 
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ΔNC16A mice develop myeloid hyperplasia 
To explain these gross alterations in spleen and bone marrow, we analyzed the 
hematopoiesis system of ΔNC16A mice by hematological examination and flow cytometry. 
Histological examination showed increased granulocytes in blood and dermis, increased 
cellularity in bone marrow, and increased red pulp in spleen of ΔNC16A mice as 
compared to WT control (Figure 2.1D). Hematological test showed significantly increased 
total cell number (Figure 2.1E) and percentage (Figure 2.1F) of granulocytes in circulation 
in ΔNC16A compared to WT mice. Normal granulocytes number range of WT mice is less 
than 20 percentage in white blood cells(37), while ΔNC16A mice manifested an 
abnormally high percentage of granulocytes in white blood cells and granulocytes number 
in the peripheral blood. Flow cytometry analysis also showed significantly increased 
granulocytes in bone marrow, spleen and peripheral blood in ΔNC16A mice as compared 
to WT controls using forward scatter (cell size) and side scatter (granularity) (Figure 2.1G) 
and granulocyte number was calculated based on surface markers CD11b and Gr.1 
(Figure 2.1H). These results demonstrated that lacking of BP180 function caused myeloid 
hyperplasia.   
 
ΔNC16A mice have more granulocyte-macrophage progenitors  
In bone marrow hematopoietic stem cells are first differentiated into common 
myeloid progenitor and granulocyte monocyte progenitor (GMP), and then differentiated 
to neutrophils, basophil and eosinophils (Figure 2.2A) (38). Since there are neutrophilia 
in ΔNC16A mice, we determined if the progenitors of granulocytes in bone marrow of 
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ΔNC16A mice were changed by flow cytometry using Lin- IL-7R-SCA-1- C-
kit+CD34+CD16+ surface markers combination panel (Figure 2.2A)(39)(40). We found that 
there was more than two folds increase in GMP population in ΔNC16A mice compared to 
WT control (Figure 2.2B), which was statistically significant (Figure 2.2C). Interestingly, 
megakaryocyte-erythrocyte progenitor (MEP) populations in ΔNC16A mice were 
significantly decreased compared to WT control (Figure 2.2B, 2.2C), which could cause 
abnormal bone marrow color change in ΔNC16A mice. By cell culture, significantly higher 
colony-forming units of granulocytes/monocytes from ΔNC16A bone marrow than WT 
control mice (Figure 2.2D). These results demonstrate that lack of BP180 leads to myeloid 
progenitor lineage skewing toward GMPs, resulting in increased granulocytes production.  
 
Granulopoiesis defects in ΔNC16A mice arise from non-cell-autonomous 
mechanism 
 
Knowing that ΔNC16A mice develop granulocyte hyperplasia, we then determined 
if the significantly elevated granulocytes came from cell-autonomous or non-cell-
autonomous mechanisms. We performed bone marrow chimera and bone marrow 
transplantation experiments. Taking advantage of congenic marker, bone marrows of 
CD45.1 WT mice and CD45.2 ΔNC16A mice were mixed at 1:1 ratio and transferred to 
sub-lethally irradiated WT CD45.1.2 recipients (Figure 2.3A). After 8 weeks reconstitution, 
there was no difference between granulocyte populations derived from WT and ΔNC16A 
mice in bone marrow and spleen of host animals (Figure 2.3B). Gr.1+ cell populations in 
bone marrow, spleen and lymph node were also comparable (Figure 2.3C). By bone 
marrow transplantation experiments, granulocyte population and Gr.1 CD11b positive 
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populations in ΔNC16A mice transplanted with WT bone marrow were similar to ΔNC16A 
mice, while WT mice transplanted with ΔNC16A bone marrow showed normal 
granulopoiesis (Figure 2.3D). These data demonstrated that altered granulocyte 
development in ΔNC16A mice was from a non-cell autonomous source.  
 
ΔNC16A mice exhibit elevated G-CSF levels and increased activation of NF-kB 
signaling pathway in bone marrow mesenchymal stem cells 
 
Since altered granulopoiesis occurs in the bone marrow stromal cell compartment, 
we determined whether BP180 is expressed in bone marrow and/or mesenchymal stem 
cells (MSC). By immunoblotting, anti-NC16A antibody detected the full-length BP180 in 
bone marrow protein extract of WT and not ΔNC16A mice, whereas anti-NC1-3 antibody 
recognized both full-length and NC16A truncated BP180 in bone marrow of both WT and 
ΔNC16A mice (Figure 2.4A). Indirect immunofluorescence using anti-NC16A antibody 
stained bone marrow cryosection from WT and not ΔNC16A mice (Figure 2.4B). Since G-
CSF is a key regulator for granulopoiesis of non-cell autonomous mechanism and myeloid 
cell proliferation (41)(42), we used ELISA and quantified G-CSF expression levels both 
in bone marrow supernatant and serum from ΔNC16A and WT mice. ΔNC16A mice had 
significantly higher G-CSF levels in bone marrow and serum compared to WT mice 
(Figure 2.4C, 2.4E). As a control, levels of GM-CSF in bone marrow and serum in 
ΔNC16A and WT mice were comparable (Figure 2.4D, 2.4F). Transcription factor NF-κB 
induces upregulation of G-CSF cytokine and pro-inflammatory cytokine (27)(28), and 
IκBα-deficient  mice had  increased granulocytes number(31). To determine whether 
activation of NF-κB pathway was also increased in ΔNC16A mice as a potential molecular 
mechanism underlying the altered granulopoiesis, we analyzed the status of NF-κB 
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signaling pathway activation in bone marrow of ΔNC16A mice by Western blot. ΔNC16A 
mice showed increased activation of JNK and IκBα since levels of phosphorylated JNK 
and IκBα in total bone marrow cell protein extracts of ΔNC16A mice were increased as 
compared to WT control (Figure 2.4G). Densitometry analysis also demonstrated 
significantly elevated phosphorylation of these signaling molecules (Figure 2.4H). To 
further confirm these findings, cultured bone marrow MSCs were assayed for activation 
of NF-kB signaling pathway and release of G-CSF. BP180 expression was detected in 
cultured bone marrow derived MSC but not granulocyte or lymphocyte (Figure 2.5A).  
Cultured bone marrow MSC from ΔNC16A mice showed significant increase of NF-κB 
signaling pathway (Figure 2.5B) and released significantly higher levels of G-CSF than 
WT mice (Figure 2.5C). In contrast, there is no significant change of GM-CSF release in 
ΔNC16A mice as compared to WT mice (Figure 2.5D). These results suggest that 
increased activation of NF-κB signaling pathway and release of G-CSF in bone marrow 
MSC contribute to the altered granulopoiesis and subsequently elevated number of 
granulocytes in bone marrow, spleen, and peripheral blood.   
 
Blocking G-CSF restores normal granulopoiesis in ΔNC16A mice  
If the increased G-CSF is critical in altered granulopoiesis in ΔNC16A mice, then 
blocking G-CSF would restore normal granulocyte level in ΔNC16A mice. To test this 
hypothesis, anti-G-CSF neutralizing antibody or matched control antibody was 
administrated i.p. into ΔNC16A mice. After 12 days, the granulocyte population in 
circulation and bone marrow of the injected mice was analyzed by hematological test and 
flow cytometry. Granulocyte number in ΔNC16A mice treated with G-CSF neutralizing 
antibody and not matched control antibody were restored to normal level by hematological 
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test (Figure 2.6A). Restored granulocyte population frequency was also observed in 
ΔNC16A mice treated with G-CSF neutralizing antibody and not matched control antibody 
(Figure 2.6B). To further investigate if the granulocyte-macrophage progenitors (GMPs) 
were restored to normal, Lin- IL-7R-SCA-1-C-kit+CD34+CD16+ surface marker 
combination panel were used by flow cytometry. As expected, the granulocyte-
macrophage progenitors (GMPs) in anti-G-CSF neutralizing antibody-treated ΔNC16A 
mice were also significantly reduced and close to levels found in WT mice (Figure 2.6C). 
These results suggest that G-CSF elevation in bone marrow is a key in myeloid 
hyperplasia in ΔNC16A mice. 
 
Granulopoiesis in K14Cre-driven skin-specific ΔNC16A mice is normal 
ΔNC16A mice start showing skin lesions at 8 weeks old. To rule out the possibility 
that altered granulopoiesis in ΔNC16A mice is secondary to skin lesion and inflammation, 
we crossed loxP floxed NC16A mice with K14Cre mice to generate mice with skin-specific 
deletion of NC16A (termed K14Cre/ΔNC16A or K14Cre/-/-). As expected, 
K14Cre/ΔNC16A mice showed NC16A truncated BP180 in the skin and full-length BP180 
in bone marrow as evidenced by immunoblotting (Figure 2.7A). Similar to ΔNC16A mice, 
K14Cre/ΔNC16A mice developed skin lesion starting at 8 weeks of age, including skin 
erosion, CD3 positive T cell and Gr.1 positive granulocyte infiltration (Figure 2.7B). By 
hematological examination granulocyte number in peripheral blood of K14Cre/ΔNC16A 
mice were compatible to WT mice (Figure 2.7C). To further characterize granulocytes in 
K14Cre/ΔNC16A mice, flow cytometry was used by forward scatter, side scatter, CD11b 
and Gr.1 to identify granulocyte populations. The granulocyte populations in K14Cre/ 
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ΔNC16A mice were comparable to WT mice (Figure 2.7D). More importantly, the 
frequency of populations in bone marrow, spleen and blood were also comparable 
between K14Cre/ΔNC16A mice and WT mice (Figure 2.7D). Furthermore, levels of G-
CSF and GM-CSF in the serum of K14Cre/ΔNC16A mice were similar to WT mice (Figure 
2.7E, 2.7F). These results demonstrated that altered granulopoiesis in ΔNC16A mice is 
caused by loss of BP180 function in bone marrow MSC and not in the skin.  
 
ΔNC16A mice at 4 weeks old show no skin lesion and exhibit abnormal 
granulopoiesis 
 
To further confirm that altered granulopoiesis in ΔNC16A mice was originated from 
bone marrow stromal cells, not skin lesion, we examined 4 week old ΔNC16A mice when 
clinical skin lesion is absent. Gross examination showed that 4 weeks old ΔNC16A mice 
do not exhibit skin abnormality and are similar to WT mice (Figure 2.9A). Histological 
examination showed no skin inflammation including the lack of CD3 positive T cell and 
granulocyte infiltration in 4 weeks old ΔNC16A mice (Figure 2.9A). Similar to 8 weeks old 
ΔNC16A mice, however, 4 weeks old ΔNC16A mice also had significantly increased 
granulocyte numbers in peripheral blood than WT mice as determined by hematological 
examination (Figure 2.9B). In addition, 4 weeks old ΔNC16A mice had more granulocytes 
in bone marrow and blood but not in the spleen or blood when compared to WT mice as 
determined by flow cytometry using forward scatter, side scatter, Gr.1 and CD11b 
markers (Figure 2.9C). Taken together, these data further suggested that altered 
granulopoiesis in ΔNC16A mice takes place in bone marrow stromal cells due to loss of 
BP180 function.  
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2.4 Discussion 
BP180 is well documented as a key cell-cell matrix adhesion molecule in the skin; 
however, other biological functions remain largely unknown (43). In this study, we 
generated a new BP180 loss-of-function mouse model (termed ΔNC16A mice) by 
deletion of NC16A domain of humanized NC16A mice (2). Using this model, we 
demonstrated that loss of BP180 function leads to altered granulopoiesis, myeloid 
progenitor lineage being skewed toward GMPs, resulting in significantly increased Gr.1 
positive granulocytes in immune organs including bone marrow, spleen and blood and 
the skin. We further showed that the altered granulopoiesis in ΔNC16A mice is caused 
by NC16A domain deletion in bone marrow. These findings suggest that BP180 as a cell-
cell matrix adhesion molecule also plays a role in granulopoiesis.   
Abnormal granulopoiesis could arise from cell-autonomous or non-cell-
autonomous (44). By bone marrow chimera and bone marrow transplantation 
experiments, we demonstrated that altered granulocyte development in ΔNC16A mice 
are from non-cell autonomous source. By western blotting we found that bone marrow 
stromal cells and not granulocytes in WT and ΔNC16A mice express BP180. G-CSF is 
the most important regulator that drives hematopoiesis stem cells to differentiate into 
common myeloid progenitor and granulocyte-macrophage progenitor (21). Granulocytes 
express G-CSF receptor (G-CSFR). Mice lacking G-CSF or G-CSFR show granulopenia 
(45)(46)(47)(48)-(49). We found that increased granulocytes in ΔNC16A mice were 
accompanied with increased level of G-CSF in bone marrow. Bone marrow MSCs from 
ΔNC16A mice also secreted significantly more G-CSF than WT control mice. Furthermore, 
treatment with anti-G-CSF neutralizing antibody restored normal granulopoiesis and 
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normal granulocyte numbers in circulation in ΔNC16A mice. Taken together, these 
findings suggest that lack of BP180 function in MSCs leads to upregulation of G-CSF and 
subsequently altered granulopoiesis. 
Transcription factor NF-kB is critical in upregulation of G-CSF and other pro-
inflammatory cytokine (27)(28). Mice lacking IκBα have increased granulocyte 
numbers(31). Cultured human keratinocytes lacking BP180 were reported to secrete 
inflammatory cytokines associated with activated NF-kB signaling pathway (50). To 
determine whether activation of NF-kB pathway is the underlying mechanism in BP180 
functional deficiency-caused increased G-CSF and granulocytes, we analyzed the status 
of NF-kB signaling pathway activation in bone marrow and bone marrow MSCs of 
ΔNC16A mice by western blot. We found an increased activation of NF-kB signaling 
pathway in ΔNC16A mice as compared to WT control mice. These results suggest that 
increased activation of NF-kB signaling pathway and release of G-CSF in bone marrow 
MSC contribute to the altered granulopoiesis and subsequently elevated number of 
granulocytes in bone marrow, spleen, and peripheral blood.      
Granulopoiesis could result from intrinsic gene regulation or extrinsic environment 
cues (51)(52)(53)(54). Periphery infection could lead to unbalanced homeostasis of 
hematopoietic stem cells, causing emergency granulopoiesis(55). ΔNC16A mice develop 
skin lesions starting at age of 8 weeks old, reducing skin barrier function that makes 
ΔNC16A mice with skin lesion more prone to infection. To rule out the possibility that 
altered granulopoiesis in 8 weeks old or older ΔNC16A mice is caused or partially 
contributed by skin lesion/skin inflammation we determined whether skin-specific NC16A 
deletion (termed K14Cre/ΔNC16A) also leads to increased granulocytes in immune 
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organs. We found that K14Cre/ΔNC16A mice phenocopied skin lesion of ΔNC16A mice 
but had normal granulopoiesis and compatible granulocyte numbers in bone marrow, 
spleen and blood as WT control mice. To further sustain that skin lesion/skin inflammation 
is not the main cause for the altered granulopoiesis in ΔNC16A mice, we quantified 
granulocytes in 4 weeks old ΔNC16A mice when no skin abnormality presents clinically 
and histologically. Like 8 weeks old ΔNC16A mice, 4 weeks old ΔNC16A mice also 
exhibited significantly increased granulocytes as compared to WT control. These results 
suggest that BP180 in bone marrow regulates normal granulopoiesis. 
Increased granulocytes in the skin and circulation are present in some of GABEB 
patients(56)(57). Mice with deletion of NC14A domain of BP180 (termed ΔNC14A mice) 
also show granulocyte infiltration in the skin (17). But, the mechanism(s) how lack of 
BP180 function in GABEB and NC14A deletion in ΔNC14A mice leads to granulocyte 
infiltration in the skin are unknown. Our current findings provide a molecular and cellular 
mechanism that explains the increased granulocytes in these pathological conditions due 
to loss of BP180 function. What the exact physiological/pathological consequence of the 
elevated infiltrating granulocytes in the skin remains to be determined.             
In summary, our results demonstrate that BP180 as a cell-cell matrix adhesion 
molecule has important activities in regulating granulopoiesis, a role which has not been 
identified previously. BP180 in bone marrow stromal cells acts on the NF-kB signaling 
pathway. Loss of BP180 function in these cells leads to increased NF-kB pathway 
activation and subsequent upregulation of G-CSF, resulting in uncontrolled 
granulopoiesis. These findings point to new directions for better understanding the 
pathophysiology of diseases associated with BP180 loss-of-function and abnormal 
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granulopoiesis.  Elucidating the precise molecular targets of BP180 should help uncover 
novel regulatory pathways.   
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Figure 2.1 Granulocyte hyperplasia in ΔNC16A mice. (A) Generation of ΔNC16 mice. 
In humanized NC16A mice (termed WT or +/+ mice), BP180 exons 18 and 19 (dark gray) 
encode the NC16A domain (dark gray) and are flanked by loxP sites. When crossed with 
germline Cre mice, Cre recombinase removes the loxP-flanked exons 18 and 19 and 
maintains the remaining reading frames, resulting in mice expressing NC16A domain 
truncated BP180 (termed ΔNC16A or -/- mice). (B) Immunoblotting. Immunoblotting 
showed that anti-NC16A antibody recognized full-length BP180 in skin of WT and not 
ΔNC16A mice, while anti-NC1-3 antibody stained both full-length BP180 in skin of WT 
and truncated BP180 in skin of ΔNC16A, confirming lack of NC16A domain of BP180 in 
ΔNC16A mice. (C) Biopsy examination of spleen and bone. Representatives of gross 
anatomy of spleen and bone marrow of WT (+/+) and ΔNC16A (-/-) mice.  Splenomegaly 
was observed in ΔNC16A mice at age of 8-12 weeks, and the bone of ΔNC16A mice was 
less red than WT mice. (D) Granulocyte infiltration. H/E staining showed increased 
granulocytes in blood, increased cellularity in bone marrow, increased red pulp in spleen, 
and increased infiltrating granulocytes in dermis of ΔNC16A mice compared to WT mice. 
(E) Hematological examination. Complete blood count showed significantly increased 
white blood cells, granulocytes and monocytes in peripheral blood of ΔNC16A mice 
compared to WT mice. (n=8, **p<0.01, ***p<0.001). WBC, white blood cell; Lym, 
lymphocyte; Mono, monocyte. BM, bone marrow. (F) Relative cell population. Percentage 
of granulocyte populations was also increased significantly, while lymphocyte population 
was significantly decreased in peripheral blood of ΔNC16A mice compared to WT mice. 
(n=8, ***p<0.001). (G) Granulocyte cell frequency. Granulocytes in bone marrow, spleen 
and blood of WT and ΔNC16A mice were analyzed by flow cytometry using forward 
scatter (cell size) and side scatter (granularity). Granulocyte populations in these three 
immune sites were around 3 folds increased in ΔNC16A mice than WT mice, and the 
increase was statistically significant (n=6, ***p<0.001). (H) Granulocyte cell number. 
Neutrophil numbers were quantified by flow cytometry using neutrophil specific surface 
markers CD11b and Gr.1. Neutrophils were significantly increased in ΔNC16A mice than 
WT mice, and the difference is statistically significant  (n=6, **p<0.01). 
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Figure 2.2 Increased granulocyte-monocyte progenitors in ΔNC16A mice. (A) 
Diagram showing different stages of granulopoiesis and surface markers expressed in 
different developmental stages. HSC, hematopoietic stem cell; MMP, multipotent 
progenitor; CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; 
MEP, megakaryocyte-erythrocyte progenitor. (B) Flow cytometry. Bone marrow cells 
were gated on Lin and IL-7R double negative cells, and c-Kit positive and Sca-1 negative 
cell population was used for further analysis. CD34 and CD16 were stained to distinguish 
GMP, CMP and MEP. Using Lin- Sca-1- c-Kit+CD34+CD16lo panel as common myeloid 
progenitor (CMP) population markers and Lin- Sca-1- c-Kit+ CD16hi as granulocyte-
monocyte progenitor(GMP) markers, GMP were more than 2 folds increased in bone 
marrow of ΔNC16A mice than WT. (C) Statistical analysis showed significantly increased 
GMP in bone marrow of ΔNC16A mice than WT, in contrast MEP were decreased in 
ΔNC16A mice than WT (n=6, ***p<0.001). (D) Bone marrow cells were cultured by 
Methycellulose-based medium, colonies were counted after 12 days culture. ΔNC16A 
mice have more granulocyte/monocyte colony-forming units (GM-CFU) than WT mice 
(n=6, ***p<0.001). 
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Figure 2.3 Granulocyte hyperplasia in ΔNC16A mice were caused by extrinsic 
factors. (A) Diagram of bone marrow chimera experiment. Bone marrows from WT 
CD45.1 and ΔNC16A CD45.2 mice were mixed by 1:1 ratio and were transferred to 
sublethally irradiated(700cGy) recipient CD45.1.2 mice by I.V. Eight weeks post 
reconstitution, surface markers were used for determining different populations of cells 
by flow cytometry.  Granulocyte populations from WT and ΔNC16A mice in bone marrow 
and spleen were comparable tested by forward scatter (cell size) and side scatter 
(granularity) (B) and by using granulocytes specific marker Gr.1+ (C). (D) Reciprocal 
transplantation experiment. WT CD45.1 bone marrow was transferred to sublethally 
irradiated (700cGy) recipient ΔNC16A CD45.2 mice, while ΔNC16A CD45.2 bone marrow 
was transferred to WT CD45.1 sublethally irradiated (700cGy) recipient mice. Total 
granulocytes were counted by hematological examination 8 weeks post bone marrow 
transplantation.  WT recipients receiving bone marrow cells either from WT or ΔNC16A 
mice had normal granulocyte numbers, while ΔNC16A recipients receiving bone marrow 
cells either from WT or ΔNC16A mice exhibited significantly higher number of 
granulocytes (n=6, ***p<0.001).  
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Figure 2.4 ΔNC16A mice showed elevated G-CSF level and increased activation of 
NF-kB signaling pathway in bone marrow. (A) Immunoblotting showed full-length 
BP180 in WT bone marrow and NC16A truncated BP180 in ΔNC16A bone marrow. (B) 
Indirect immunofluorescence exhibited anti-NC16A antibody staining in WT and not 
ΔNC16A bone marrow. ELISA assays revealed significantly elevated levels of G-CSF in 
bone marrow (C) and blood (E) of ΔNC16A mice as compared to WT control, whereas 
levels of GM-CSF in bone marrow (D) and blood (F) of both WT and ΔNC16A mice were 
compatible (n=8, *p<0.05,  ***p<0.001). (G) Protein extracts made from total bone marrow 
cells (whole bone marrow flush) of WT and ΔNC16A mice were analyzed by 
immunoblotting. Higher levels of phospho-JNK and phospho-IκBα were seen in ΔNC16A 
mice than in WT mice. (H) Phosphorylated IκBα and JNK and not p38 were significantly 
increased in bone marrow of ΔNC16A mice than in WT mice as determined by 
densitometry analysis of the phosphorylated vs. total signaling proteins. n=4, **p<0.01.   
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Figure 2.5 Bone marrow-derived mesenchymal stem cells (MSC) from ΔNC16A 
mice showed increased activation of NF-kB pathway and secreted higher level of 
G-CSF.  (A) Immunoblotting identified BP180 in MSC and not granulocytes (GC) and 
lymphocytes (LC). Immunoblotting showed increase p-IκBα level in bone marrow derived 
MSC of ΔNC16A mice compared to WT control. (B) ELISA assays of MSC culture medium 
revealed significantly higher levels of G-CSF in bone marrow derived MSC of ΔNC16A 
mice as compared to WT control (n=6, ***p<0.001) (C). Levels of bone marrow derived 
MSC-released GM-CSF were similar between WT and ΔNC16A mice (D).  
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Figure 2.6 Blocking G-CSF restored normal granulopoiesis in ΔNC16A mice. WT 
and ΔNC16A mice were i.p. treated with anti-G-CSF neutralizing antibody or matched 
control antibody. Granulocytes and GMP were analyzed by hematological examination 
and flow cytometry at day 12 post treatment. (A) Complete cell count. Hematological test 
showed that anti-G-CSF antibody and not control antibody treatment reduced granulocyte 
population in ΔNC16A mice down to level similar to WT mice after 12 days treatment (n=6. 
***p<0.001). PBS-treated WT and ΔNC16A mice were used as control. (B) Flow 
cytometry using CD11b and Gr.1 surface markers showed that anti-G-CSF neutralizing 
antibody and not control antibody treatment restored granulocyte level in ΔNC16A mice 
comparable to WT control mice. (C) Flow cytometry using Lin, Sca-1, c-Kit CD16 and 
CD34 markers showed that granulocyte monocyte progenitor (GMP) level in bone marrow 
of ΔNC16A mice was also restored to the level of WT control 12 days after anti-G-CSF 
antibody and not control antibody treatment.  
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Figure 2.7 K14Cre/ΔNC16A mice had normal granulopoiesis.   (A) Immunoblotting 
confirmed that K14Cre/ΔNC16A mice (K14Cre/-/-) express NC16A truncated BP180 in 
the skin and full-length BP180 in bone marrow.  (B) Like ΔNC16A mice, 8 weeks old 
K14Cre/-/- mice show skin lesion clinically and skin inflammation histologically by H/E 
staining. Immunofluorescence identified infiltrating CD3 positive T cells and Gr.1 positive 
granulocytes in the skin of K14Cre/-/- and ΔNC16A mice but not WT control mice. (C) 
Hematological examination showed that K14Cre/-/- mice had significantly lower periphery 
granulocytes compared to ΔNC16A mice (n=6, ***p<0.001), which is similar to WT. (D) 
Using flow cytometry for Gr.1 and CD11b double positive cell, K14Cre/-/- and WT mice 
had compatible granulocyte populations in bone marrow, spleen and blood (n=6). ELISA 
assays revealed similar levels of serum G-CSF (E) and GM-CSF (F) between K14Cre/-/- 
and WT mice (n=6, ***p<0.001, K14Cre/-/- vs. ΔNC16A). 
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Figure 2.8 Characterization of ΔNC16A mice (A) Clinical examination. At the age of 8-
12 weeks, ΔNC16A mice started developing clinical phenotypes, including retarded 
growth and skin lesions. (B) Body weight. ΔNC16A mice (-/-) exhibited retarded growth 
compared to WT (+/+) and heterozygote (+/-) littermates, showing here female mice at 
age of 8 weeks old. (n= 12, *p<0.05). (C) Spleen body weight ratio.  Spleen weight and 
body weight of ΔNC16A and WT mice were measured at age of 8-12 weeks. The 
spleen/body weight ratio was significantly elevated in ΔNC16A mice (n=8, **p<0.01). 
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Figure 2.9 Four week old ΔNC16A mice showed no skin lesion and altered 
granulopoiesis. (A) 4 week old ΔNC16A mice showed no skin lesion clinically, no skin 
inflammation by H/E, and no infiltrating CD3 positive T cell and Gr.1 positive granulocytes 
in the skin by indirect immunofluorescence.  (B) Hematological examination demonstrated 
significantly increased granulocyte numbers in peripheral blood of 4 and 8 week old 
ΔNC16A mice compared to age-matched WT mice (n=6, ***p<0.001). (C) Flow cytometry 
using Gr.1 and CD11b surface markers showed that 4 weeks old ΔNC16A mice had 
significantly increased granulocyte population in bone marrow and blood as compared to 
4 weeks old WT mice (n=6, *p<0.05, **p<0.01).   
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Figure 2.10 Increased autoantibody and affected B cell development in ΔNC16A 
mice. (A) Anti-NC16A autoantibody elevated around 7 folds in ΔNC16A mice compared 
to WT control (n=7,p<0.001) test by in-house ELISA.  (B) Also, total serum IgE level 
elevated significantly. (n=7, p<0.001). (C) Flow cytometry test B cell development in 
bone marrow. Using Hardy’s strategy by multiple color panel CD43, B220, HAS, BP-1 
and IgM to distinct different B cell development stages, it showed B cell development 
were impaired start from pre-pro B cell stage in ΔNC16A mice, but ΔNC16A mice still 
have mature population in bone marrow. (D) Cell number. Calculate cell number in 
bone marrow, it showed B cell number were significantly decreased in different stages 
in ΔNC16A mice compared to WT control. (n=7. ***p<0.001) 
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Figure 2.11 Decreased B cell populations in ΔNC16A mice.  (A) Spleen B cell 
populations were tested by flow cytometry. It showed decreased transit B cell 
populations and marginal zone B cell population in ΔNC16A mice compared to WT 
mice. But, there are more pre-marginal zone B cells in ΔNC16A mice compared to WT 
(B) Cell number of B cell in spleen of ΔNC16A mice is also decreased compared to WT 
mice in total B cell, transit stages and marginal zone B cells.  (n=7. ***p<0.05) 
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CHAPTER 3: NLRP3 inflammasome activation is required for the cutaneous 
autoimmune disease bullous pemphigoid1 
 
3.1 Introduction 
 
Bullous pemphigoid (BP) is the most common skin autoimmune blistering disease. 
It is a potentially fatal disease, and mainly affects the elderly with increased incidence as 
aging(1). BP is characterized by subepidermal blisters, a dermal inflammatory infiltrate, 
and in vivo deposition of autoantibodies and complement components along the 
basement membrane zone (BMZ)(2)(3)(4)(5). Eosinophils, neutrophils, lymphocytes, 
mast cells, and monocyte/macrophages are present in the lesional/perilesional skin of 
BP(3). Various proinflammatory mediators that recruit and activate inflammatory cells 
have also been identified in lesional skin and/or blister fluids of BP patients, including C5a, 
TNF-α, IL1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8. 
BP autoantibodies target two hemidesmosomal proteins: BP230, an intracellular 
protein of the plakin protein family, and BP180 (also termed type XVII collagen). 
(2)(3)(4)(5). BP180 is a transmembrane homo-trimeric glycoprotein with a subunit MW of 
180 kDa. Its C-terminal ectodomain consists of a long collagenous stretch interrupted and 
flanked by 16 non-collagen sequences. The membrane-proximal non-collagen linker 
domain (termed NC16A) harbors multiple epitopes recognized by BP autoantibodies. 
Although the human BP180 shares high overall homology with the murine BP180, the 
                                                          
1 This project was initiated by a previous lab member (Dr. Peng Geng) and my contributions were focused 
on in vitro study and also involved in in vivo study using NC16A mice models. 
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NC16A domain is very poorly conserved in the murine protein (termed NC14A), resulting 
in a lack of immune-reactivity cross these two species.  
Experimental BP was originally developed by passive transfer of rabbit antibody 
against murine BP180NC14A domain into neonatal mice. Subsequently, anti-
BP180NC16A autoantibodies from BP patients were also demonstrated to be pathogenic 
in humanized BP180 and NC16A mice (6) (7). Subepidermal blistering in experimental 
BP is initiated by pathogenic antibody binding to BP180 on basal keratinocytes that leads 
to complement activation to generate C5a. C5a acts on C5aR on mast cells leading to 
mast cell degranulation and release of TNF-α and other proinflammatory cytokines. 
Infiltrating neutrophils release proteolytic enzymes causing tissue injury and 
subepidermal blistering(8)(9).       
IL-1β, a cytokine secreted in early stage of BP, is critical for recruitment of 
neutrophils and other leukocytes by modulating chemokine secretion such as IL-8 (10) 
(12).  IL-1β is produced as an inactive cytoplasmic precursor that is processed to the 
mature active form by caspase-1 of inflammasomes(11)(12). The inflammasomes are 
components of the innate immune system that sense danger- and pathogen-associated 
molecular patterns and respond to cellular stress by producing the pro-inflammatory 
cytokines IL-1β and IL-18. Four types of inflammasome have been extensively studied: 
the NLRP1, NLRP3, NLRC4, and the absent in melanoma 2 (AIM2) inflammasomes(13) 
(14). These inflammasomes contain the bipartitie adaptor protein ASC that is required for 
the interaction between NLRs/absent in melanoma 2 and caspase-1. Whereas NLRP1 
and NLRC4 can be activated by microbial stimuli such as anthrax lethal toxin and 
Salmonella sp., respectively, AIM2 is activated by the presence of DNA in the 
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cytoplasm(13)(15)(16). The NLRP3 inflammasome is currently the most widely 
investigated inflammasome. It is activated by an ever-expanding list of diverse stimuli 
including extracellular adenosine triphosphate (ATP)(17), gout-associated monosodium 
urate (MSU) crystals(18), asbestos, silica(19), alum(20), and titanium dioxide, nigericin, 
and Candida albicans(21)(22)(23). Inflammasome activation occurs in primarily in 
immune cells such as macrophages and dendritic cells. NLRP3 activation was also 
reported in human keratinocytes. The inflammasome is crucial for the regulation of 
inflammatory process. Inflammasomes have been implicated in numerous diseases 
including metabolic disorders such as diabetes, obesity and atherosclerosis, and 
autoimmune diseases such as multiple sclerosis and lupus(24)(25)(26). However, the role 
of inflammasomes in skin autoimmune blistering disease has not been investigated.   
In this study, we used animal models of BP and showed that NLRP3 
inflammasome is required for subepidermal blister formation through regulation of IL-1β 
processing and subsequent neutrophil infiltration. We also demonstrated that blockade 
of IL-1β-IL-1R interaction could be a new therapeutic strategy for BP.
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3.2 Materials and methods 
Mice 
C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, ME). 
Humanized NC16A mice were generated as described (7). NLRP3-/-, ASC-/-, and 
Caspase-1-/-, mice were described(27)(28). Caspase-11-/- andNLRC4-/- mice were 
described(29). NLRP3 -/-/NC16A mice were generated by crossing NLRP3-/- with NC16A 
mice. All the mice were on C57BL/6J background and hosted under specific pathogen-
free conditions in the animal facilities of the University of North Carolina, Chapel Hill. 
Animal care and animal experiments were conducted in accordance with the Animal Care 
Committee at the University of North Carolina, Chapel Hill.  
 
IgG passive transfer and animal evaluation 
Rabbit anti-mBP180NC14A (R530) antibodies were generated by our laboratory as 
described(30). Anti-hBP180 autoantibodies were purified from BP patient’s serum. IgG 
fractions from sera of the immunized rabbits and BP were purified using a protein G 
Sepharose column (Sigma). BP180NC16A-specific IgG were further purified using a 
BP180NC16A-glutathione Sepharose column(8). To induce BP in neonatal mice, a 50 l 
aliquot of sterile IgG (control rabbit IgG, anti-mNC14A IgG, control human IgG, or BP IgG) 
in PBS was administered to neonatal mice by i.d. injection. The mouse skin was examined 
24h after injection.  The extent of cutaneous disease was scored as follows: "(-)", no 
detectable skin disease; "1+", mild erythematous reaction with no evidence of the 
"epidermal detachment" sign; "2+", intense erythema and "epidermal detachment" sign 
involving 10-50% of the epidermis in localized areas; and "3+", intense erythema with 
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frank "epidermal detachment" sign involving more than 50% of the epidermis. To induce 
BP in adult mice, IgG preparations (25 μl in PBS) were injected into the ear of adult mice 
(8-12 weeks old). The mice were examined 24h post injection.  
After clinical examination, the animals were sacrificed, and skin and serum 
specimens were obtained. The skin sections were used for routine histological 
examination by light microscopy (H/E staining) to localize the lesional site and neutrophil 
infiltration. Direct IF assays were done to detect deposition of human or rabbit IgG or 
mouse C3 at the basement membrane zone(31).  
In some IgG passive transfer experiments, mice were pretreated with anti-IL-1α, 
anti-IL-1β neutralizing antibodies or matched control antibody (R&D Systems), IL-1R 
antagonist Anakinra (Kineret; Swedish Orphan Biovitrum AB, Stockholm, Sweden) 
(32)(33), pan-caspase inhibitor z-VAD, caspase-1-specific inhibitor z-YVAD or control z-
FA-fmk (Enzo life science, Farmingdale, NY). The mice were injected i.d with pathogenic 
antibodies 90 minutes post treatment.   
 
Quantification of infiltrating neutrophils 
For quantification of neutrophil accumulation in the skin, tissue MPO activity in skin 
sites of the injected animals was assayed as described(34)(35), using purified MPO as 
standard. MPO content was expressed as relative MPO activity (OD460nm reading/mg 
protein of the mouse skin injected with pathogenic anti-mBP180 IgG minus OD460nm 
reading/mg protein of the mouse skin injected with control IgG).  Protein concentrations 
were determined by the Bio-Rad dye-binding assay using BSA as a standard.  
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 Quantification of levels of TNF-α, IL-1α, IL-1β and C5a in blister fluids.  
One hundred microliters of PBS was injected into the skin blisters (formed 12 hours 
after pathogenic IgG injection) and nonlesional sites, and withdrawn 1 minute later. The 
“washout” PBS was centrifuged at low speed (1,000 g) for 5 minutes to remove cells and 
then high speed (12,000 g) for 5 minutes to remove cell debris(36). The supernatant was 
analyzed for the levels of released TNF-α, IL-1α, IL-1β and C5a in the skin by ELISAs 
(R&D Systems).  
 
Detection of activated caspase-1 and IL-1β in cultured keratinocytes 
Primary keratinocytes were isolated from new born NC16A and NLRP3-deficient 
NC16A mice and were cultured in Keratinocyte Serum Free medium (Gibco) 
supplemented with prequalified human recombinant epidermal growth factor and bovine 
pituitary extract(37). The HaCaT keratinocytes were cultured in DMEM containing 10% 
FBS. Keratinocytes were incubated at 37°C in a humidified atmosphere with 5% CO2 and 
used for experiments when reaching 80-90% confluence. Keratinocytes were stimulated 
with TNF-α (100 ng/ml), pathogenic antibody or health control antibody (2 mg/ml), or 
medium control for 24 hours. To block caspase-1 activity, cells were pretreated with pan-
caspase inhibitor z-VAD, caspase-1-specific inhibitor z-YVAD or control z-FA-fmk (50uM). 
Cells were pelleted and total cell protein extracts were probed for activated caspase-1 
and IL-1β by immunoblotting. Cell culture supernatants were analyzed for released IL-1β 
by ELISA.  
Immunoblotting for caspase-1 and IL-1β were performed by using standard 
techniques as previously described (38). The anti-caspase-1 antibody and anti-IL-1β 
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antibody were purchased from Santa Cruz. After secondary antibody incubation, the 
membrane was developed by ECL reagents (GE healthcare life sciences, PA).  
 
Statistical analysis 
The data are expressed as mean ± SEM and were analyzed using the Student’s t-
test. A p value less than 0.05 was considered significant. 
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3.3 Results 
Levels of TNF-α, IL-1α and IL-1β are increased in rabbit anti-mNC14A IgG-induced 
BP 
 
BP patients have significantly increased levels of proinflammatory cytokines 
including IL-1α,IL-1β, IL-6, IL-8, and TNF-α in blister fluids and/or circulation (26-33)(39). 
Using ELISA assays, we found that levels of TNF-α, IL-α and IL-1β were also dramatically 
increased in blister fluids of C57BL/6J mice injected with pathogenic rabbit anti-mNC14A 
IG as compared to mice injected with control IgG (Figure 3.1).  
 
TNF-α upregulates IL-1α and IL-1β expression and is indispensable for rabbit anti-
mNC14A IgG-induced BP 
 
To determine whether increased TNF-α level is required in experimental BP, we 
injected pathogenic rabbit anti-mNC14A IgG into WT and TNF-α-deficient (TNF-α-/-) mice. 
As expected, pathogenic IgG-injected WT mice developed clinical blister and had in situ 
deposition of rabbit IgG and mouse C3 at the BMZ (Figure 3.2A, panels a-c). In contrast, 
pathogenic IgG-injected TNF-α-/- mice showed no skin abnormality although IgG and C3 
were deposited at the BMZ (Figure 3.2A, panel d-f). Furthermore, levels of IL-1α and IL-
1β in the skin of pathogenic IgG-injected TNF-α-/- mice were markedly reduced as 
compared to those in the blister fluids of the diseased mice (Figure 3.2B). These results 
suggest that rabbit anti-mNC14A IgG-induced BP depends on TNF-α which is required 
for increased IL-1α and IL-1β and possibly other proinflammatory cytokines.   
 
 
NLRP3 inflammasome is essential for rabbit anti-mNC14A IgG-induced BP 
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IL-1β maturation and secretion could be regulated by NLRP3 inflammasome. To 
determine whether NLRP3 inflammasome is required for IL-1 β maturation and secretion 
and experimental BP, we tested pathogenic activity of rabbit anti-mNC14A IgG in mice 
lacking the key NLRP3 inflammasome components NLRP3 (NLRP3-/-), ASC (ASC-/-), or 
caspase-1 (caspase-1-/-). Pathogenic IgG-injected WT mice developed clinical blister and 
had in situ deposition of rabbit IgG and mouse C3 at the BMZ (Figure 3.3A, panels a-c). 
In contrast, pathogenic IgG-injected NLRP3-/-, ASC-/-, and caspase-1-/- mice showed no 
skin abnormality although IgG and C3 were deposited at the BMZ (Figure 3.3A, panel d-
l). We also ruled out the involvement of caspase-11 and NLRC4 inflammasome in 
experimental BP: mice lacking capase-11 or NLRC4 were susceptible for rabbit anti-
mNC14A IgG-induced blistering (Figure 3.3B). Without NLRP3 inflammasome, levels of 
the released IL-1β (Figure 3.3B) and infiltrating neutrophils (Figure 3.3C) in the non-
diseased skin of NLRP3-/-, ASC-/-, and caspase-1-/- mice were significantly reduced as 
compared to those in blister fluids of diseased WT, NLRC4-/- and caspase-11-/- mice. 
These demonstrate that NLRP3 inflammasome plays an important role in IL-1β 
production and subepidermal blistering in rabbit anti-mNC14A IgG-induced BP.  
 
Anti-NC16A IgG autoantibody-induced BP also requires NLRP3 inflammasome  
Anti-NC16A autoantibody-induced BP in humanized NC16A mice is very similar (if 
not identical) immunopathologically to rabbit anti-mNC14A IgG-induced BP(8). To 
investigate the role of NLRP3 in a more clinically relevant BP model, we crossed NC16A 
with NLRP3-/- mice to generate NC16A/NLRP3-/- mice.  Like rabbit anti-mNC14A IgG-
induced BP model, anti-NC16A IgG induced subepidermal blistering in NC16A mice and 
not in -injected NC16A/NLRP3-/- mice, although both groups of mice showed similar 
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human IgG deposition at the BMZ (Figure 3.4A). Clinical disease score of 
NC16A/NLRP3-/- mice was significantly lower than that of the diseased WT mice (Figure 
3.4B). There was no difference in C3 deposition between two groups of mice by direct IF 
(Figure 3.4C). Levels of C5a in the skin were also comparable between NC16A/NLRP3-
/- mice and NC16A mice at 4 h post IgG injection, the early stage of pathogenic IgG-
induced inflammation; NC16A/NLRP3-/- mice, however, had significantly reduced C5a 
levels in the skin compared to WT mice at 24h due to lack of the late (amplification) stage 
of pathogenic IgG-induced inflammation seen in WT control (Figure 3.4D). Similarly, 
NC16A/NLRP3-/- mice showed the same levels of TNF-α as WT mice at 4 h but 
significantly reduced levels of TNF-α relative to WT mice at 24 h post IgG injection (Figure 
3.4E).  Without NLRP3, however, levels of the released IL-1β (Figure 3.4F) and infiltrating 
neutrophils (Figure 3.4G) in NC16A/NLRP3-/- mice were significantly reduced at both 4 h 
and 24 h post IgG injection. These results suggest that NLRP3 inflammasom is required 
in anti-NC16A autoantibody-induced BP, and lack of NLRP3 inflammasome activity leads 
to reduction of mature IL-1β without interrupting pathogenic IgG binding, complement 
activation and upregulation of TNF-α.   
 
Activation of NLRP3 inflammasome occurs in pathogenic anti-NC16A IgG-treated 
keratinocytes  
 
The findings that mice lacking NLRP3 are resistant to experimental BP associated 
with a reduced level of mature IL-1β in the skin strongly suggest that NLRP3 
inflammasome activation is a necessary step in BP. To further confirm this conclusion, 
we determine whether pathogenic antibodies cause NLRP3 inflammasome activation in 
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keratinocytes at molecular level. Keratinocytes isolated from NC16A and NC16A/NLRP3-
/- mice were incubated with pathogenic anti-NC16A IgG or control normal human IgG in 
the presence or absence of TNF-α. Protein extracts of cultured keratinocytes were 
analyzed for activated caspase-1 and IL-1β by immunoblotting, and levels of released IL-
1β in cultured cell supernatants were quantified by ELISA. Immunoblotting identified 
active capase-1 and IL-1β in NC16A and not NC16A/NLRP3-/- keratinocytes treated with 
pathogenic and not control IgG in the presence of TNF-α (Figure 3.5A, lane 4). ELISA 
revealed significantly higher levels of released IL-1β in NC16A keratinocytes treated with 
pathogenic IgG in the presence of TNF-α as compared to NC16A keratinocytes treated 
with control IgG plus TNF-α and NC16A/NLRP3-/- keratinocytes treated with pathogenic 
plus TNF-α (Figure 3.5B, bar 3 vs. bars 2, 6). Furthermore, treatment of pan-caspase 
inhibitor and caspase-1-specific inhibitor abolished IL-1β release by NC16A keratinocytes 
stimulated with pathogenic IgG plus TNF-α (Figure 3.5B, bars 4, 5).  In addition, human 
keratinocytes HaCat cells treated with pathogenic IgG plus TNF-α also exhibited bands 
of active caspase-1 and IL-1β by immunoblotting (Figure 3.5C). These results suggest 
that NLRP3 inflammasome is activated in experimental BP and is required for increased 
release of IL-1β and subsequent subepidermal blistering in BP. 
 
IL-1β and not IL-1α is required for rabbit anti-mNC14A IgG-induced BP 
To determine whether IL-1α and IL-1β are involved in and what their relative 
contributions are to experimental BP, we first compared the disease activity between IL-
1R-deficient (IL-1R-/-) and WT mice. Pathogenic rabbit anti-mNC14A IgG-injected IL-1R-
/- mice showed no skin disease as compared to extensive BP blistering in pathogenic IgG-
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injected WT mice at 24h post IgG injection (Figure 3.7A, 3.7C). We then pretreated WT 
mice with anti-IL-1α, anti-IL-1β neutralizing antibody or matched control antibody, 
followed by i.d. injection of pathogenic rabbit anti-mNC14A IgG. Mice treated with control 
antibody or anti-IL-1α neutralizing antibody showed comparable BP disease activity 
(Figure 3.7B, panels a and b, 3.7C), whereas anti-IL-1β neutralizing antibody-treated 
mice became resistant to experimental BP (Figure 3.7B, panel c, 3.7C). By ELISA, the 
levels of released IL-1β in non-diseased skin of IL-1R-/- and anti-IL-1β neutralizing 
antibody-treated WT mice were significantly reduced as compared to those in blister fluids 
of diseased mice treated with anti-IL-1α neutralizing antibody or control antibody (Figure 
3.7D).  MPO enzyme activity assay revealed significantly lower number of infiltrating 
neutrophils in non-diseased skin of IL-1R-/- and anti-IL-1β neutralizing antibody-treated 
WT mice as compared to diseased skin of anti-IL-1α neutralizing antibody or control 
antibody-treated mice (Figure 3.7E). These results demonstrate that increased IL-1β 
mediated by TNF-α is required for experimental BP.   
 
Blockade of caspase-1 and IL-1β abolishes anti-NC16A IgG-induced BP in NC16A 
mice 
  
Pathogenic anti-NC16A autoantibodies activate NLRP3 inflammasome in 
experimental BP; thus, blocking activity of caspase-1 and IL-1β should abolish or reduce 
BP disease. The next sets of experiments show exactly what we expected. Anti-NC16A 
IgG induced BP blister in control and not pan-caspase inhibitor and caspase-1-specific 
inhibitor-treated NC16A mice (Figure 3.6A). Non-diseased skin of control-treated mice 
showed significantly reduced levels of released IL-1β (Figure 3.6B) and infiltrating 
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neutrophils (Figure 3.6C) as compared to those in diseased-skin of pan-caspase inhibitor 
and caspase-1-specific inhibitor-treated mice at 24 h post IgG injection. Reduction in 
levels of the released IL-1β and infiltrating neutrophils was caspase-1 dose dependent 
(Figure 3.6B, 3.6C, bars 3-5). Similarly, blockade of IL-1β-IL-1R interaction by the IL-1R 
antagonist Anakinra also abolished BP blistering without interfering with IgG and C3 
deposition at the BMZ (Figure 3.8A). Anakinra-treated NC16A mice showed much lower 
clinical disease score that control mice at 6, 12 and 24 h post IgG injection (Figure 3.8B). 
Anakinra-treated NC16A mice showed much lower clinical disease score that control mice 
at 6, 12 and 24 h post IgG injection (Figure 3.8B). Levels of released IL-1β in the skin of 
Anakinra-treated NC16A mice were comparable to control mice at 6 h but significantly 
reduced at 12 and 24 h post IgG injection compared to control mice (Figure 3.8B). MPO 
enzyme assay revealed significantly reduced neutrophil infiltration in the non-diseased 
skin of Anakinra-treated NC16A mice as compared to diseased skin of control mice at 6, 
12, and 24 h post IgG injection (Figure 3.8C).  Taken together, NLRP3 inflammasome-
mediated IL-1β processing is crucial for neutrophil recruitment and subsequent 
subepidermal blistering, and targeting caspase-1 and IL-1β could be therapeutic for BP.  
 
 
83 
 
3.4 Discussion 
Our results demonstrate that activation of NLRP3 inflammasome is required for 
experimental BP. The defect in NLRP3 inflammasome activation affects the pathogenic 
antibody-induced production of mature IL-1β and subsequent neutrophil recruitment, 
abolishing the skin disease. This study is the first to link NLRP3 inflammasome as a key 
player in the cutaneous autoimmune blistering disease BP.   
BP is an autoantibody-mediated inflammatory subepidermal blistering disease 
(2)(3)(4)(5). Proinflammatory mediators such as C5a, TNF-α, IL1α, IL-1β, IL-6, and IL-8 
are present in the lesional skin and blister fluids of BP [26-33]. In murine models of BP 
induced by rabbit anti-mNC14A IgG in B6 mice and by anti-NC16A autoantibody in 
humanized NC16A mice, subepidermal blister formation depends on complement 
activation, mast cell degranulation and neutrophil infiltration. Mast cells, upon activation 
through C5a-C5aR interaction, release TNF-α and other proinflammatory cytokines to 
recruit neutrophils (40). Like human BP, TNF-α and IL-1α and IL-1β are also significantly 
elevated in the lesional skin and blister fluids of mouse BP. The increased levels of IL-1α 
and IL-1β in the lesional site of the diseased mice depends on TNF-α since pathogenic 
antibody-injected TNF-α-deficient mice exhibit drastically reduced levels of IL-1α and IL-
1β in the skin. Although both IL-1α and IL-1β act on IL-1R (41), only IL-1β-IL-1R 
interaction pathway is required for experimental BP, in that pathogenic antibodies are 
able to induce BP in mice lacking IL-1α and not mice lacking IL-1β or IL-1R. Furthermore, 
the IL-1R antagonist Anakinra, a clinically approved drug for rheumatoid arthritis protects 
mice from experimental BP. Our results identify TNF-α-IL-1β-IL-1R axis to be crucial for 
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recruiting neutrophils and subsequent BP blistering in BP animal model and suggest that 
these molecules could be new therapeutic targets for BP. 
Mice lacking NLRP3, ASC, or caspase-1 become resistant to experimental BP 
associated with significantly reduced level of mature IL-1β. Deficiency of NLRP3 only 
affects IL-1β processing and release since NLRP3-deficient mice injected with pathogenic 
antibodies still show similar antibody binding, complement activation and increased level 
of TNF-α in the skin as pathogenic antibody-injected WT mice at the early stage of the 
disease development. Like NLRP3 inflammasome, the NLRC4 inflammasome also 
consists of ASC and caspase-1 components(42); but, NCRC4-deficient mice show the 
same susceptibility to experimental BP as WT control, establishing the specificity of 
NLRP3 inflammasome being critical in experimental BP.  Mice with caspase-1 deletion 
also lack caspase 11(43), and caspase-11 is capable of processing pro-IL-1β (44). In 
experimental BP, however, caspase-1 is the major enzyme to proteolytically convert pro-
IL-1β to the active mature form as caspase-11-deficient mice injected with pathogenic 
antibodies develop the same severity of BP disease as WT control. Activation of NLRP3 
inflammasome in experimental BP is further sustained by our in vitro results: release of 
mature IL-1β by pathogenic antibody-treated cultured keratinocytes also depends on 
NLRP3, ASC and caspase-1.              
NLRP3 inflammasome-mediated processing of IL-1β requires two signals, priming 
cells to upregulate pro-IL-1β expression and activation of NLRP3 inflammasome (45). 
TLR agonists and TNF-α are well-known for their priming activity(46). In experimental BP, 
mast cell-derived TNF-α is required for pathogenic antibody-induced IL-1β upregulation 
and subsequent neutrophil infiltration and blistering. The second signal could be 
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pathogenic antibodies. Our in vitro experiments prove this is the case. Cultured 
keratinocytes treated only with both TNF-α and pathogenic antibodies exhibit caspase-1 
activation and maturation and release of IL-1β. Our in vitro results also suggest that TNF-
α and pathogenic antibodies synergize in providing a potent priming signal in pro-IL1-β 
production since a minimal level of pro-IL1-β is seen in keratinocytes treated with TNF-α 
alone or TNF-α plus control antibody. NLRP3 and other inflammasomes have been 
extensively characterized in cells of the myeloid lineage, such as macrophages and 
dendritic cells (47). NLRP3 inflammasome can be activated by multiple and diverse 
stimuli including ATP(17), gout-associated monosodium urate (MSU) crystals(18), 
asbestos, silica(19), alum(20), titanium dioxide, nigericin, and Candida 
albicans(21)(22)(23). Cholesterol crystals induce TNF-α/C5a-dependent NLRP3 
inflammasome activation in human monocytes(48). Keratinocytes exposed to skin 
irritants or ultraviolet V irradiation triggers NLRP3 inflammasome activation(47)(49) In this 
study, we show autoantibodies, upon binding to the hemidesmosomal protein BP180 in 
basal keratinocytes and in concert with TNF-α, is capable of activating NLRP3 
inflammasome. How anti-BP180 autoantibodies activate NLRP3 inflammasome in this 
pathological setting remains to be determined. 
NLRP3 inflammasome is involved in a number of autoimmune diseases, including 
vitiligo(50)(51), Addison disease, type 1 diabetes(52), celiac disease(23), systemic 
sclerosis(53), MS/EAE(54), and inflammatory bowel disease(55) Our results demonstrate 
that pathogenic anti-BP180 antibodies cause activation of NLRP3 inflammasome in basal 
keratinocytes, and NLRP3 inflammasome plays a pivotal role in initiation of IL-1β-
mediated skin inflammasome and subsequent neutrophil infiltration and subepidermal 
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blister formation. These findings are important for better understanding the molecular and 
cellular pathogenesis of BP and point to new directions for the development of therapies 
for this potentially fatal disease.   
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Figure 3.1 Increased levels of TNF-α, IL-1α and IL-1β in blister fluid of mouse BP. 
Neonatal C57BL/6J mice were injected with control rabbit IgG or pathogenic rabbit anti-
mBP180 IgG R530 (2.5 mg/g body weight) and examined 24 h post injection. ELISA 
assays showed significantly increased levels of TNF-, IL-1α and IL-1β in the blister fluid 
of the diseased mice as compared to that in the “wash-out” of control mice. n=6, *p<0.01. 
 
 
 
92 
 
 
Figure 3.2 Increased IL-1 depends on TNF-α in experimental BP. Neonatal WT (+/+) 
and TNF--deficient (TNF--/-) mice were injected i.d. with control IgG or pathogenic 
rabbit anti-mBP180 IgG R530 (2.5 mg/g body weight) and examined 24 h post injection. 
A. Clinical examination showed BP-like blister in pathogenic IgG-injected +/+ (panel a) 
and not TNF--/- mice (panel d). Direct IF exhibited that the skin of both pathogenic IgG-
injected +/+ (panels b, c) and TNF--/- mice (panels e f) had in situ deposition of rabbit 
IgG and mouse C3 at the basement membrane zone (BMZ). B. ELISA assays revealed 
significantly reduced levels of TNF-, IL-1α and IL-1β in the “wash-out” of pathogenic 
IgG-injected TNF--/- mice as compared to in the blister fluid of the diseased mice. n=6, 
*p<0.01. 
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Figure 3.3 Rabbit anti-mBP180 IgG-injected mice lacking NLRP3 inflammasome 
activation are resistant to experimental BP. Adult (8-10 weeks old) WT and mice 
lacking NLRP3 (NLRP3-/-), ASC (ASC-/-), caspase 1 (Caspase-1-/-), caspase 11 
(Caspase-11-/-), NLRC4 (NLRC4-/-) were injected i.d. with control IgG or pathogenic 
rabbit anti-mBP180 IgG R530 (2.5 mg/g body weight) and examined 24 h post injection. 
A. Histological examination revealed dermal-epidermal separation in pathogenic IgG-
injected WT (panel a) and not NLRP3-/-, ASC-/-, and Caspase-1-/- mice (panels b-d). 
Pathogenic IgG-injected Caspase-11-/- and NLRC4-/- mice developed BP blistering 
similar to WT (data not shown). Direct IF exhibited in situ deposition of rabbit IgG and 
mouse C3 at the BMZ of the skin of all pathogenic IgG-injected mice (panels e-l). B. 
ELISA assay showed significantly reduced levels of IL-1β in the “wash-out” of 
pathogenic IgG-injected NLRP3-/-, ASC-/-, and Caspase-1-/- mice (bars 2-4) compared to 
WT, Caspase-11-/- and NLRC4-/- mice (bars 1, 5, 6). C. MPO assay exhibited a 
significantly increased number of infiltrating neutrophils in the lesional skin of 
pathogenic IgG-injected WT, Caspase-11-/- and NLRC4-/- mice (bars 1, 5, 6) relative to 
the non-lesional skin of NLRP3-/-, ASC-/-, and Caspase-1-/- mice (bars 2-4). n=6, *p<0.01 
(bar 1 vs. bars 2-4). 
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Figure 3.4 Anti-NC16A IgG autoantibody-injected NC16A mice lacking NLRP3 
inflammasome activation are resistant to experimental BP. Neonatal NC16A (+/+) 
and NC16A lacking NLRP3 (NC16A/NLRP3-/-, -/-) mice were injected i.d. with control IgG 
or pathogenic anti-NC16A IgG autoantibodies (0.29 mg/g body weight) and examined 24 
h post injection. A. Clinical examination showed BP-like blister in pathogenic IgG-injected 
+/+ (panel a) and not -/- mice (panel d). Direct IF exhibited human IgG deposition at the 
BMZ of pathogenic IgG-injected +/+ (panel b) and not -/- mice (panel e). H/E staining 
revealed dermal-epidermal separation in pathogenic IgG-injected +/+ (panel c) and not -
/- mice (panel f). B. Pathogenic IgG-injected +/+ mice developed more severe clinical 
disease than -/- mice. C. ELISA assay showed significantly reduced levels of IL-1β in the 
“wash-out” of pathogenic IgG-injected -/- mice compared to blister fluid of the diseased 
WT mice. D. MPO enzyme activity assay exhibited that infiltrating neutrophils in the skin 
of pathogenic IgG-injected -/- mice were significantly lower than the disease +/+ mice. E. 
Direct IF demonstrated deposition of mouse C3 at the BMZ of both pathogenic IgG-
injected +/+ (panel b) and -/-mice (panel d). ELISA assays revealed that at 4 h post IgG 
injection, pathogenic IgG-injected +/+ and -/- mice had similar skin levels of C5a (F) and 
TNF-α (G), but at 24 h pathogenic IgG-injected -/- mice had significantly reduced levels 
of C5a and TNF-α when compared to pathogenic IgG-injected +/+ mice. n=8, *p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
Figure 3.5 Activation of NLRP3 inflammasome in experimental BP. Mouse primary 
keratinocytes from NC16A (+/+) and NC16A/NLRP3-/- (-/-) mice and human keratinocytes 
HaCat cells were stimulated with pathogenic BP autoantibody or normal human IgG (2 
mg/ml) in the presence of TNF-α (100 ng/ml). After 24 h stimulation, cell protein extracts 
were probed for activated caspase-1 and IL-1β by western blot. Released IL-1β in the cell 
culture supernatants were quantified by ELISA. A. Western blot. In the presence of TNF-
α pathogenic IgG stimulated +/+ (lane 4) and not -/- (lane 2) mouse keratinocyte showed 
activated caspase-1 (p-10) and IL-1β (p17) bands. Keratinocytes from +/+ mice alone 
(lane 1) or treated with normal control IgG (lane 3) did not show activated caspase-1 and 
IL-1 β bands. B. ELISA. High levels of IL-1β were released by pathogenic IgG stimulated 
+/+ (bar 3) and not -/- (bar 6) mouse keratinocytes. Pan-caspase inhibitor z-VAD (50 uM) 
and caspase-1-specific inhibitor z-YVAD (50 uM) significantly inhibited IL-1β secretion by 
pathogenic IgG stimulated +/+ mouse keratinocytes (bars 4, 5). n=3, *p<0.01. C. Western 
blot. In the presence of TNF-α pathogenic IgG (2 mg/ml for lane 3, 10 mg/ml for lane 4) 
stimulated human keratinocytes showed activated caspase-1 (p-10) and IL-1β (p17) 
bands. Keratinocytes with mock control (lane 1), treated with TNF-α alone (lane 2), or 
normal human control (lane 5) did not show activated caspase-1 and IL-1 β bands. 
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Figure 3.6 Blockade of caspase-1 abolishes anti-NC16A IgG-induced BP in NC16A 
mice. Neonatal NC16A mice were pretreated with pan-caspase inhibitor z-VAD (5 μg/g 
body weight), caspase-1-specific inhibitor z-YVAD (1-5 μg/g body weight) or control (5 
μg/g body weight) and then injected i.d. with pathogenic anti-NC16A IgG autoantibodies 
(0.29 mg/g body weight). The mice were examined 24 h post IgG injection. A. Clinical 
examination showed that mice treated with control (panel a) and not pan-caspase inhibitor 
(panel b) and caspase-1-specific inhibitor (panel c) developed BP-like blister. B. ELISA 
assay showed significantly reduced levels of IL-1β in the “wash-out” of caspase inhibitor-
treated mice (bars 2-5) compared to blister fluid of control-treated mice (bar 1). The 
inhibition of caspase-1-specific inhibitor was dose-dependent (bars 3-5). C. MPO enzyme 
activity assay exhibited that infiltrating neutrophils in the skin of caspase inhibitor-treated 
mice (bars 2-5) were significantly lower than the diseased control-treated mice (bar 1). 
n=8, *p<0.05, **p<0.01, *p<0.001. 
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Figure 3.7 IL-1β-IL-1R interaction is required for experimental BP. Neonatal WT and 
IL-1 receptor-deficient (IL-1R-/-) mice were injected i.d. with control IgG or pathogenic 
rabbit anti-mBP180 IgG R530 (2.5 mg/g body weight). WT mice were also pretreated with 
PBS, anti-IL-1α neutralizing antibody, anti-IL-1β neutralizing antibody, or control antibody 
(1 μg/g body weight) and then injected i.d. with pathogenic rabbit anti-mBP180 IgG R530 
(2.5 mg/g body weight). The mice were examined 24 h post pathogenic IgG injection. A. 
Pathogenic IgG-injected WT (panel a) and not IL-1R-/- (panel b) mice showed dermal-
epidermal separation. B. WT mice treated with control antibody (panel a) or anti-IL-1α 
neutralizing antibody (panel b) and not anti-IL-1β neutralizing antibody (panel c) 
developed BP-like blister. C. Pathogenic IgG-injected IL-1R-/- mice (bar 5) and +/+ 
pretreated with anti-IL-1β neutralizing antibody (bar 4) developed significantly less severe 
clinical disease than pathogenic IgG-injected +/+ mice pretreated with PBS, control IgG 
or anti-IL1α neutralizing antibody (bars 1-3). D. ELISA assay showed significantly 
reduced levels of IL-1β in the “wash-out” of the skin of IL-1R-/- mice (bar 5) and +/+ 
pretreated with anti-IL-1β neutralizing antibody (bar 4) as compared to blister fluid in 
pathogenic IgG-injected +/+ mice pretreated with PBS, control IgG or anti-IL1α 
neutralizing antibody (bars 1-3). E. MPO enzyme activity assay exhibited that infiltrating 
neutrophils in the skin of IL-1R-/- mice (bar 5) and +/+ mice pretreated with anti-IL-1β 
neutralizing antibody (bar 4) were significantly lower than the diseased mice pretreated 
with PBS, control IgG or anti-IL1α neutralizing antibody (bars 1-3). n=8, *p<0.01. 
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Figure 3.8 IL-1R antagonist Anakinra blocks anti-NC16A IgG-induced BP in NC16A 
mice. Neonatal NC16A mice were pretreated with Anakinra or control (1 μg/g body weight) 
and then injected i.d. with pathogenic anti-NC16A IgG autoantibodies (0.29 mg/g body 
weight). The mice were examined at 6, 12 and 24 h post IgG injection. A. Clinical 
examination showed that mice treated with Anakinra (panel a) and not control (panel d) 
failed to develop BP-like blister 24 h post pathogenic IgG injection. Direct IF exhibited 
deposition of human IgG and mouse C3 at BMZ of both groups of mice (panels b, c, e, f). 
B. Anakinra treatment significantly inhibited pathogenic IgG-induced clinical disease 
activity at all time points examined. C. ELISA assay showed comparable levels of IL-1 β 
at 6 h and significantly reduced levels of IL-1β at 12 h and 24 h in the skin of Anakinra-
treated mice compared to control-treated mice. D. MPO enzyme activity assay exhibited 
that infiltrating neutrophils in the skin of Anakinra-treated mice (bars 2-5) were 
significantly lower than the control-treated mice at all time points examined. n=8, *p<0.05, 
**p<0.01, *p<0.001. 
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
4.1 Summary of findings 
BP180 is a cell-matrix adhesion molecule, and mainly functions as a 
hemidesmosomal protein. Other functions of BP180 are still largely unknown. In this study, 
we demonstrated a novel function of BP180 working on signaling pathway. Bone marrow 
stromal cells deficient in BP180 lead to a highly activated NF-kB signaling pathway, which 
resulted in increased secretion of G-CSF in bone marrow and peripheral blood. The 
increased G-CSF resulted in granulopoiesis, and increased granulocyte infiltration to 
immune organs and skin. These findings for the first time illustrate the mechanism related 
to the clinical pathophysiology in GABEB patients with gene BP180 mutations, and 
provide potential methods for diagnosis, treatment and prevention of disease. 
Furthermore, we also discovered B cell development changes and autoimmunity in 
BP180 gene deficient mice, which would lead to a tool to investigate the relationship 
between inflammation and autoimmunity. 
Bullous pemphigoid is an autoimmune blistering disease, characterized by 
autoantibodies binding to BP180, complement deposition in the basement membrane and 
PMN infiltration, which causes separation of the epidermis and dermis. Previous studies 
in this laboratory demonstrated that autoantibodies trigger complement activation, which 
works on mast cells in our animal model. The activated mast cell releases cytokines and 
recruits PMN to the skin; however, the mechanism of how mast cells recruit PMN is still 
unclear.  In this study, we demonstrate that the NLRP3 inflammasome in skin 
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keratinocytes is involved in BP, evidenced by caspase-1 activation and IL-1β secretion. 
Without the NLRP3 inflammasome components, mice resist development of BP, without 
affecting antibody binding or complement deposition in the basement membrane. We also 
demonstrate that IL-1R is essential for disease development and an IL-1R antagonist is 
a potential treatment for BP. These findings for the first time elucidate the role of the 
NLRP3 inflammasome in BP and provide a potential therapy for disease.  
 
4.2 New function of BP180 
BP180 is a type II transmembrane protein, and mainly functions as a 
hemidesmosomal protein, evidenced by association with two types of diseases, 
generalized atrophic benign epidermolysis bullosa (GABEB) and bullous pemphigoid 
(BP). In GABEB, the BP180 gene is mutated, while in bullous pemphigoid, autoantibodies 
recognized BP180, mainly the NC16A domain. To elucidate the pathogenesis of GABEB, 
BP and the function of BP180, an NC16A gene deficient mouse strain was established. 
In this study, we explored granulopoiesis in this mouse strain, which to our knowledge 
had not been investigated. BP180 is mainly expressed in skin basal keratinocytes as a 
component of the hemidesmosome; however, BP180 is also expressed in a variety of 
normal tissues that have an epithelial component(1)(2)(3). Details have been described 
in Chapter 1, 1.4. Previous reports show that BP180 modulates keratinocyte expression 
of proinflammatory cytokines and chemokines(4). In BP180 gene deficient patient 
keratinocytes, and in shRNA-mediated knockdown of BP180 in normal keratinocytes, we 
found enhanced proinflammatory cytokine IL-8 concentration in mRNA and protein levels 
by a mechanism independent of integrin. Furthermore, using inhibitors and luciferase 
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experiments, the authors showed NF-kB and p38MAPK are involved in this scenario(4); 
however the mechanism is still elusive. In this study, we discovered enhanced expression 
of p-JNK MAPK and p-IkBα in bone marrow stromal cells of the BP180 gene deficient 
mouse.  This leads to more G-CSF secretion and altered granulopoiesis. However, we 
still did not answer why hemidesmosomal protein BP180 gene disruption leads to more 
innate immune responses in this mouse strain. Recognition of microbial infection leads to 
transcription of host defense genes in what is termed the host response. A recent report 
shows structural damage in the C. elegans epidermis causes release of STA-2 
transcription factor and induction of an innate immune response, which for the first time 
implicates that hemidesmosome integrity is monitored by a transcription factor for the 
detection of epidermal infection(5). Cellular components, like actin, tubulin cytoskeletons, 
intermediate filaments and hemidesmosomes may be subject to surveillance of infection, 
injury and danger signaling. The authors also tested primary keratinocytes and found 
disrupted hemidesmosome induction of β-defensin and pro-inflammatory cytokines IL-6 
and IL-8. This is the strong evidence that hemidesmosomal proteins might be involved in 
host defense and chronic inflammatory conditions(5)(6). Neutrophils are the first defense 
players of innate immunity in vertebrates. Whether the BP180 gene deficient mouse’s 
production of more granulocytes is related to hemidesmosome integrity, which leads to 
other transcription factors (either downstream or upstream of NF-kB), like STAT3 and 
STAT5B activation and induction of granulopoiesis would be an interesting topic for 
further investigation.  
Both GABEB and BP patients have been reported with inflammatory cell infiltration 
in skin. In this study we showed abnormal granulopoiesis in ΔNC16A mice, by mechanism 
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that NF-kB transcription factor is highly activated in bone marrow stromal cells. However, 
whether or not the functions of granulocytes in ΔNC16A mice have been changed is 
unclear. Details of neutrophil function have been described in Chapter 1, 2.3 and 2.4. In 
addition to bone marrow granulopoiesis, granulocyte migration, life cycle and release of 
granules also regulate granulocyte number. Release of neutrophils is delicately regulated 
by the chemokine signaling pathway, CXCL12-CXCR4 and CXCL2-CXCR2 pairs of 
ligands and receptors(7). Retention of neutrophils in bone marrow is controlled by 
CXCL12-CXCR4, while CXCL2-CXCR2 promotes release of neutrophils from bone 
marrow to the periphery(7). Neutrophils have at least three distinct granule subsets: 
primary or azurophilic granules (neutrophil elastase) and myeloperoxidases (MPO); 
secondary or specific granules, lactoferrin; tertiary or gelatinase granules (MMP2, 
MMP9)(8).  Those distinct granule subsets are based on stage or tissue specific 
transcription factors which govern the successive expression of genes for granule 
proteins at different times(8)(9). AML-1 is critical for primary granule protein expression, 
while C/EBPε regulates secondary and tertiary granule protein expression(9).   
In the previous reports, there are four types of granules, including elastase, 
cathepsin, collagenase, and gelatinase B(10)(11)(12). Different granules could regulate 
each other by specific mechanisms. In the bullous pemphigoid animal model, we report 
GB and NE are required for subepidermal blister formation by degradation of BP180, 
independent neutrophil migration(13)(14). To deeply dissect the function of neutrophils in 
bullous pemphigoid, Dr. Liu and colleagues used neutrophil transplantation experiments, 
and in vivo, and in vitro BP180 degradation assay, found that GB acts upstream of NE. 
More importantly, Dr. Liu found mechanism that GB regulates NE through the inactivated 
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NE inhibitor α1-PI. All of these granule regulation events need to be initiated by BP180 
autoantibodies(15). Since we already found BP180 initiated granulopoiesis in bone 
marrow stromal cells, whether BP180 affects granulocyte function would be a very 
interesting topic for future studies.  
 
4.3 Granulocytes in B cell development and a possible mechanism in autoimmune 
diseases 
 
Autoimmune disease is a significant cause of morbidity and mortality and might 
affect 5-10% of the world population(16)(17). Autoimmune diseases arise from tolerance 
checkpoints that are broken and the relentless growth of self-reactive B and T 
lymphocytes. Bullous pemphigoid (BP) is a human skin blistering autoimmune and 
inflammatory disease. A hallmark of BP is deposition of autoantibodies and complement 
components along the basement membrane zone of the skin. In this study, we discovered 
granulopoiesis in BP180 gene deficient mice and also B cell development impairment 
might result in the production of autoantibody (Figure 2.10, 2.11). B cell development 
throughout adult life occurs within the bone marrow microenvironment. B cell 
development has been discussed in Chapter 1, 2.5.  CXCL12 is a soluble factor, isolated 
from stromal cell lines, and used for B cell development culture in vitro(18)(19). The 
receptor for CXCL12 is CXCR4. Gene mutations of CXCL12 and CXCR4 have shown B-
cell development is abnormal, especially for pre-pro-B cell stage in the mouse 
model(20)(21)(22). The CXCL12-CXCR4 axis is essential for the earliest stages of B-cell 
development. This raises the possibility that CXCL12 attracts and/or tethers precursors 
immediately after commitment to the B-cell lineage in an appropriate niche. G-CSF 
produced by bone marrow stromal cells is capable of inducing a reduction of CXCL12, 
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due mostly to its degradation by neutrophil elastase (MMP9)(23). The early stage 
development of B cells is associated with autoantibody production, since surrogate light-
chain-deficient mice harbored elevated levels of autoantibodies(24).  In this study, we 
observed B cell development is impaired in the earliest stage (pre-pro-B, pro-B, pre-B, 
immature B), and granulopoiesis in bone marrow. We hypothesized that more 
granulocytes secrete more neutrophil elastase in BP180 gene deficient mice bone 
marrow that leads to degradation of CXCL12, which is critical for B cell development and 
mobility to the appropriate niche, induction of autoimmunity.  We will be able to test this 
hypothesis by BP180 and MMP9 double gene deficient mice. Also, G-CSF could act 
through a monocytic cell intermediate reprogramming of stromal cells in bone marrow, by 
which decreases CXCL12 and suppresses B lymphopoiesis(25). How granulopoiesis 
alters B-cell lymphopoiesis and produces autoantibodies would be an interesting topic 
that needs to be investigated in the future.  
 
4.4 Possible inflammasome mechanism in experimental BP 
Previous reports demonstrated that inflammasomes play a role in 
autoinflammation and autoimmunity diseases. Mechanisms of NLRP3 inflammasome 
activation, associated diseases and therapeutics have been discussed in Chapter 1, 4.2 
and 4.3. In this study, we found that the NLRP3 inflammasome is critical for development 
of bullous pemphigoid disease. Furthermore we demonstrated caspase-1 activation and 
IL-1β secretion is expressed BP180 keratinocytes upon pathogenic IgG stimulation; 
however the caspase-1 activation mechanisms have not been deeply investigated. BP-
IgG complex internalization by endocytosis would interact with lysosome in cells. 
111 
 
Lysosomal rupture releases Capthepsin B, the proteinase that degrades collagen and 
also is able to activate NLRP3 inflammasome assembly(26).  
 Also, whether the NLRP3 inflammasome is activated in mast cells or 
macrophages has not been extensively tested. Mast cells play a very important role in the 
pathogenesis of bullous pemphigoid by mechanisms that secrete TNF-α  et al cytokines 
via phosphorylation of p38 induction of degranulation(27)(28)(29). TNF-α and cross-
linked pathogenic IgG could be the first and second signals for inflammasome activation 
respectively(29) . Macrophages as a major innate immunity player have been extensively 
investigated for inflammasome activation. Previous findings also report that macrophages 
are important for recruitment of neutrophils to form skin blisters in bullous pemphigoid by 
mast cell independent mechanisms(27). To investigate the function of the inflammasome 
in macrophages, NLRP3 deficiency and sufficiency in a macrophage mouse model could 
be used. However, it is hard to demonstrate a direct relationship between pathogenic IgG 
and macrophages in vitro. Whether keratinocytes, mast cells and macrophages play a 
synergistic role or inflammasome activation involves a hierarchical sequence would be a 
very interesting topic to be investigated.  
More importantly, in this study, we demonstrated the IL-1R antagonist, Anakinra is 
able to prevent and treat bullous pemphigoid, which suggests a new treatment for clinical 
therapy. Current therapy for bullous pemphigoid mainly counts on corticosteroids and 
immunosuppressive agents. However, high-dose corticosteroids are poorly tolerated in 
the elderly and long-term treatments may cause numerous dose-related adverse effects, 
such as immune suppression, severe infection, diabetes mellitus, osteoporosis, 
hypertension, and renal failure(30). Our elucidated molecular mechanisms provide a 
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scientific basis for use of Anakinra treatment for bullous pemphigoid in the clinical setting 
and advance the knowledge of the pathogenic mechanism for bullous pemphigoid, which 
would resolve the suffering of patients.  
Autoinflammatory diseases are driven by endogenous danger signals, metabolic 
mediators and cytokines, whereas autoimmunity involves the activation of T and B cells, 
the latter requiring V-(D)-J recombination of receptor-chain gene segments for maturation. 
Most of the time, autoinflammatory diseases are driven by IL-1β and IL-18, however, 
autoimmunity is associated with type I interferon signatures in the blood(31)(32). IL-1β 
and IL-18 can also shape adaptive immunity. IL-1β could act on lymphocyte IL-2 receptor 
expression, prolonging T cell survival and enhancing antibody production by B cells and 
increasing B cell proliferation. Also, Inflammasome activation could drive Th1 and Th17 
cell differentiation and amplification. Due to Inflammasome activation, secretion of IL-1β 
and IL-18 is involved in multiple steps of T or B cell proliferation and differentiation, this 
will facilitate identification of potentially new therapeutic reagents for autoimmune 
diseases.  
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